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ABSTRACT 
The immune system protects the host from microbial attacks and malignant 
transformation. The antimicrobial defence system consists of innate and adaptive 
immune responses. The innate system is activated by recognition of conserved 
structures found in pathogens but not in the host itself. Monocyte/macrophages, 
natural killer (NK) cells, and dendritic cells (DCs) are key players in the innate 
immune response. Macrophages directly phagocytose and destroy infectious agents, 
and NK cells destroy virus-infected or malignant cells by cytolysis. DCs capture and 
process microbe-derived foreign antigens. Subsequently they move to local lymph 
nodes to present the antigens to naive T cells, thus activating antigen-specific T and 
B cell responses. During the innate response macrophages, NK cells, and DCs 
produce cytokines that guide the ongoing innate immune responses, and stimulate 
the initiation of the adaptive immune response. 
Cytokines are a group of intercellular signaling proteins that regulate cellular 
proliferation, differentiation, and immune responses. The extracellular cytokine 
signal from the cell surface receptor into the nucleus is transmitted via receptor-
coupled signal transduction systems. The Janus kinasesignal transducer and 
activator of transcription (JAKSTAT) pathway is the system most widely used by 
cytokines. Other signaling pathways and transcription factors are also activated by 
cytokines, including the interferon regulatory factors (IRFs). The signals from all 
activated pathways converge in the nucleus. In eukaryotic cells, the availability of 
regulatory DNA elements to transcription factors and the transcriptional machinery 
is regulated by covalent modification of DNA-associated histone proteins and, in 
some cases, the DNA itself.  
Receptors, signalling proteins, and transcription factors are the molecules that enable 
the cells to interpret incoming signals and respond to these signals by regulated 
changes in their transcriptional profiles. These changes can for example lead to 
secretion of cytokines or other signaling proteins or enhance proliferation of the cell. 
During cellular differentiation, various genes are expressed in a stage-specific 
  
manner, and abrupt changes in the expression levels of given genes can occur when 
the cells shift from one developmental stage to another. 
In this work, expression and activation of STAT and IRF family transcription factors 
was studied in human immune cells. This work shows that interferon (IFN) 
stimulation increased the expression of signalling components essential for IFN 
responses, Stat1, Stat2, and IRF9, leading to an enhanced IFN-response. IFNs are 
cytokines produced by cells during microbial infections. This kind of a positive 
feedback mechanism may be one means by which the IFN-system strengthens the 
innate immune response. Additionally, differentiation of monocytes into 
macrophages was characterized. Differentiation was found to significantly alter the 
cells responsiveness to the growth-promoting cytokine granulocyte/macrophage 
colony-stimulating factor (GM-CSF). Significantly reduced activation of Stat5 by 
GM-CSF and decreased expression of its target genes in macrophages was detected. 
Decreased Stat5 activation in macrophages may be one mechanism by which the 
expression of monocyte-specific genes is prevented when the cells differentiate. In 
this work it is also shown that in NK and T cells, cytokines induced the expression 
of IRF1, IRF4, and IRF8 transcription factors. IRF4 expression was regulated by 
Stat4, and a Stat4-binding DNA-element was described in the IRF4 promoter region. 
STAT and IRF expression was also studied in monocytes, macrophages, and DCs. 
IRF4 and Stat4 transcription factors were found to be constitutively expressed in 
DCs but not in macrophages. The functionality of several IRF4 promoter DNA-
elements was also characterized in DCs. 
This thesis work provides information on how cytokines regulate the functions of 
immune cells. Regulation of transcription factor expression and activation in cells 
ensures that cell type-specific cytokine responses are initiated in an orderly fashion. 
Ultimately, the interplay between STATs and IRFs allows the cells to prolong and 
fine-tune the effect of the cytokine signals they receive. 
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TIIVISTELMÄ 
Immuunijärjestelmän tehtävänä on suojella yksilöä taudinaiheuttajilta ja  
pahanlaatuisilta solumuutoksilta. Immuunivaste jakautuu synnynnäiseen ja 
hankittuun immuniteettiin. Monosyytit, makrofagit, dendriitti- ja NK-solut ovat 
veren valkosoluja, joilla on synnynnäisessä immuunivasteessa tärkeitä tehtäviä. 
Makrofagit fagosytoivat ja tuhoavat taudinaiheuttajia, ja NK-solut tuhoavat virusten 
infektoimia tai pahanlaatuisiksi muuntuneita soluja. Dendriittisolut esittelevät 
vieraat mikrobiantigeenit T- ja B-soluille aikaansaaden antigeenispesifisen hankitun 
immuniteetin aktivoitumisen. Aktivoituneet monosyytit, makrofagit, dendriitti- ja 
NK-solut tuottavat liukoisia välittäjämolekyylejä, sytokiineja, jotka säätelevät 
solujen kasvua ja erilaistumista sekä tulehdusreaktioiden ja immuunipuolustuksen 
aktivoitumista. Sytokiinien signaalinvälitys tapahtuu tarkoin säädellysti. 
Sytokiinisignaali siirtyy solun sisällä useimmiten JAKSTAT-reitin välityksellä. 
STAT-proteiinit ovat sytoplasmisia transkriptiotekijöitä, jotka aktivoituvat 
sytokiinin sitoutuessa reseptoriinsa, muodostavat keskenään dimeerejä ja siirtyvät 
tumaan. Tumassa ne säätelevät sytokiinien kohdegeenien ilmentymistä. Sytokiinit 
aktivoivat myös muita signaalireittejä ja säätelyproteiineja, kuten IRF-
transkriptiotekijöitä. Eukaryoottisoluissa geenien ilmentymistä säädellään myös 
muokkaamalla DNA:ta sitovia histoniproteiineja. Näin säädellään sitä, kuinka 
helposti transkriptiotekijät pääsevät sitoutumaan kohteenaan oleviin DNA-
elementteihin geenien säätelyalueilla. 
Solujen toiminnan kannalta on tärkeää, mitä pintareseptoreja, signaalinvälitys-
molekyylejä ja transkriptiotekijöitä solussa ilmennetään, sillä näiden molekyylien 
avulla solu kykenee muuntamaan ympäristöstä tulevat signaalit muutoksiksi solun 
geenien ilmentymisessä. Muutos geenien ilmentymisprofiilissa vaikuttaa solun 
toimintaan, ja voi esimerkiksi saada aikaan tiettyjen proteiinien erittämisen solusta 
tai muutoksia solun kasvupotentiaalissa. Esimerkiksi erilaistumisen aikana soluissa 
ilmennetään kussakin kehitysvaiheessa tarvittavia proteiineja, ja eriasteisesti 
erilaistuneiden solujen geenien ilmentymisessä voi olla suuriakin eroja. 
  
Tässä väitöskirjatyössä on tutkittu STAT- ja IRF-perheen transkriptiotekijöiden 
ilmentymistä ja aktivaatiota ihmisen immuunijärjestelmän soluissa. Ensimmäisessä 
osatyössä havaittiin, että interferonistimulaatio voimisti interferonien 
signaalinvälitykseen osallistuvien transkriptiotekijöiden, Stat1:n, Stat2:n ja IRF9:n, 
ilmentymistä makrofageissa, mikä johti voimistuneeseen interferonivasteeseen. 
Interferonit ovat sytokiineja, joita solut tuottavat infektioiden yhteydessä. Tällaisen 
positiivisen takaisinkytkentämekanismin avulla solut voivat tehokkaammin taistella 
taudinaiheuttajia vastaan, ja se voi olla yksi tapa, jolla interferonit voimistavat 
synnynnäistä immuniteettia. Toisessa osatyössä tarkasteltiin monosyyttien 
erilaistumista makrofageiksi. Tässä työssä havaittiin, että monosyyttien ja 
erilaistuneiden makrofagien vaste GM-CSF-kasvutekijälle on erilainen. GM-CSF 
aktivoi Stat5-transkriptiotekijän monosyyteissä voimakkaammin kuin 
makrofageissa. Samoin Stat5:n aktivoimien kohdegeenien ilmentyminen 
monosyyteissä oli tehokkaampaa kuin makrofageissa. Stat5-aktivaation 
vaimentuminen liittyi erilaistumiseen monosyytistä makrofagiksi. Tämä saattaa olla 
eräs mekanismi, jolla estetään monosyyttispesifisten geenien ilmentyminen 
makrofageissa. Kolmannessa osatyössä tarkasteltiin IRF-transkriptiotekijöiden 
ilmentymistä ihmisen NK- ja T-soluissa. IRF4 on T-solujen erilaistumiselle ja 
toiminnalle välttämätön proteiini. Sen ilmentyminen aktivoituu, kun T-solu tunnistaa 
spesifisen antigeeninsa. Tämän työn päähavainto oli, että myös sytokiinit 
voimistavat IRF4-transkriptiotekijän ilmentymistä NK- ja T-soluissa. Tämä tapahtuu 
Stat4-transkriptiotekijän välityksellä, ja työssä kuvattiin myös IRF4-geenin 
säätelyalueelta DNA-elementti, johon Stat4-proteiini sitoutuu. Neljännessä 
osatyössä tutkittiin STAT- ja IRF-transkriptiotekijöiden ilmentymistä ja aktivaatiota 
monosyyteissä, makrofageissa ja dendriittisoluissa. Työssä havaittiin, että Stat4 ja 
IRF4 ilmentyvät dendriittisoluissa, mutta eivät makrofageissa. Lisäksi työssä 
karakterisoitiin IRF4-geenin säätelyalueelta useita eri transkriptiotekijöitä sitovia 
DNA-elementtejä ja analysoitiin niiden toimivuutta IRF4-geenin ilmentymisen 
säätelyssä dendriittisoluissa.  
Tämä väitöskirjatyö syventää tietämystä siitä, kuinka sytokiinit säätelevät 
immuunipuolustuksen kannalta tärkeiden solujen toimintaa. Säätelemällä 
transkriptiotekijöiden ilmentymistä ja aktivaatiota soluissa varmistetaan, että oikea-
aikainen, solytyyppikohtainen sytokiinivaste käynnistyy tarkoituksenmukaisella 
tavalla immuunivasteen aikana. 
 
Avainsanat: immuunijärjestelmä, verisolut, välittäjäaine, geeninsäätely, 
transkriptiotekijä 
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ABBREVIATIONS 
APC  antigen presenting cell 
CBP  CREB binding protein 
CD  cluster of differentiation 
cDNA  complementary DNA 
ChIP  chromatin immunoprecipitation 
CML  chronic myeloid leukemia 
CNTF  ciliary neurotrophic factor 
CREB  cyclic AMP response element binding protein 
CSF  colony stimulating factor 
CTL  cytotoxic T lymphocyte 
DC  dendritic cell 
EGF  epidermal growth factor 
EMSA  electrophoretic mobility shift assay 
EPO  erythropoietin 
ERK  extracellular signal regulated kinase 
FCS  fetal calf serum 
FGF  fibroblast growth factor 
GAS  IFN-γ activated sequence element 
G-CSF  granulocyte colony stimulating factor 
GH  growth hormone 
GM-CSF  granulocyte-macrophage CSF 
HAT  histone acetyl transferase 
HDAC  histone deacetylase 
HMG  high mobility group 
HTLV  human T cell leukemia virus 
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Ig  immunoglobulin 
IFN  interferon 
IKK  inhibitory κB kinase 
IL  interleukin 
IRF  interferon regulatory factor 
ISGF  interferon stimulated gene factor 
ISRE  interferon stimulated response element 
IU  international unit 
JAK  Janus tyrosine kinase 
JNK  c-Jun N-terminal kinase 
LIF  leukemia inhibitory factor 
LPS  lipopolysaccharide 
mAb  monoclonal antibody 
MAPK  mitogen-activated protein kinase 
M-CSF  macrophage colony stimulating factor 
MHC  major histocompatibility complex 
mRNA  messenger RNA 
NFAT  nuclear factor of activated T cells 
NF-κB  nuclear factor-κB 
NK  natural killer 
OSM  oncostatin M 
PAGE  polyacrylamide gel electrophoresis 
PBMC  peripheral blood mononuclear cell 
PBS  phosphate buffered saline 
PCAF  p300/CBP associated factor 
PCR  polymerase chain reaction 
PDGF  platelet-derived growth factor 
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PIAS  protein inhibitor of activated STATs 
PRL  prolactin 
RT-PCR  reverse transcriptase-PCR 
SDS  sodium dodecyl sulphate 
SH2  src homology region 2 
SHP-1  SH2 domain-containing phosphatase-1 
SOCS  suppressor of cytokine signaling 
STAT  signal transducer and activator of transcription 
SUMO  small ubiquitin-like protein modifier 
TCR  T cell receptor 
TGF  transforming growth factor 
Th  T helper 
TLR  Toll-like receptor 
TNF  tumor necrosis factor 
TPO  thrombopoietin 
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1 INTRODUCTION 
The immune response can be divided into two arms: innate and adaptive responses. 
The innate system provides the first line of defence against pathogens. The 
activation of innate responses relies on recognition of conserved structures found in 
pathogens, called pathogen-associated molecular patterns, to distinguish between 
self and the invading microorganism. This recognition is mainly mediated by Toll-
like receptors (TLRs) present on the cell surface of dendritic cells (DCs) and 
macrophages. Monocyte/macrophages and natural killer (NK) cells function in the 
heart of the innate immune response. Macrophages act as scavengers by directly 
phagocytosing and destroying infectious agents, and NK cells destroy virus-infected 
or malignant cells by cytolysis. DCs are antigen-presenting cells that capture and 
process microbe-derived foreign antigens. Subsequently they move to local lymph 
nodes to present antigens to naive T cells, thus activating antigen-specific immune 
responses. Macrophages, NK cells, and DCs produce cytokines that guide the 
ongoing innate immune responses, and stimulate the initiation of the adaptive 
immune response by T and B cells, the cell types able to recognize and respond to 
specific antigens.  
Cytokines are a group of intercellular signaling proteins that play important roles in 
regulating cell homeostasis and immune responses. The extracellular cytokine signal 
has to be transmitted from the cell surface into the nucleus via receptor-coupled 
signal transduction systems. The Janus kinasesignal transducer and activator of 
transcription (JAKSTAT) pathway is the system most widely used by cytokines. 
Other signaling pathways and transcription factors activated by cytokines include 
the mitogen-activated protein kinase (MAPK) pathway, the nuclear factor (NF)-κB-
system, and the interferon regulatory factors (IRFs). The signals from all these 
pathways converge in the nucleus to produce regulated changes in the cells 
transcriptional profiles. However, transcription factors are not the only molecules 
regulating gene expression. In eukaryotic cells, DNA and interacting proteins form a 
dynamic structure called chromatin. The availability of regulatory DNA elements to 
transcription factors and RNA polymerase II in the chromatin context is regulated by 
covalent modification of DNA-associated proteins and, in some cases, the DNA 
itself.  
Transcriptional activity of transcription factors can be modulated in several ways. 
One is the activation of pre-existing proteins by covalent modifications. Additional 
modifications may also serve to stabilize the interactions between DNA and proteins 
to prolong the time of transcriptional activation. The activity of a given transcription 
factor can be targeted to a subset of immune cells by cell type-specific expression, 
 16 
enabling the formation of specific transcription factor complexes exclusively in that 
cell type. Another possibility is to modulate the availability of transcription factors 
by up- or down-regulating their expression levels. Such transcription factor cascades 
give the possibility to robustly regulate a second wave of target genes after inducible 
or constitutively expressed inhibitory proteins have terminated the initiating 
stimulus. All of these strategies are used by cytokines in their signal transduction in 
target cells and some of them are also demonstrated in this work.  
In this work, cells of the human immune system, monocytes, macrophages, DCs, 
NK and T cells, were used as a cell model. Expression and activation of STAT and 
IRF family transcription factors in response to cytokine stimulation was studied in 
these cells. Also, the effect of differentiation of monocytes to macrophages or DCs 
on STAT and IRF expression and activity was characterized. Interferon (IFN) 
stimulation increased the expression of signalling components essential for IFN 
responses, Stat1, Stat2, and IRF9, thus providing a mechanism for positive feedback 
in the IFN system. Differentiation of monocytes into macrophages was found to 
significantly alter the responsiveness of the cells to the growth-promoting cytokine 
granulocyte/macrophage colony-stimulating factor (GM-CSF), leading to 
significantly reduced activation of Stat5 and decreased expression of its target genes 
in macrophages. In NK and T cells, cytokines induced the expression of IRF1, IRF4, 
and IRF8 via STAT activation. IRF4 and Stat4 transcription factors were 
constitutively expressed only in DCs but not in macrophages.  
IRFs and STATs bind to distinct DNA elements. They have both common and 
unique target genes.   Activation of the JAKSTAT pathway in response to cytokine 
stimulation is usually short-lived. When IRF expression in the cell is up-regulated 
by STATs, the expression of target genes common to both STATs and IRFs can be 
regulated even though the initiating cytokine signal has already disappeared. Also, a 
second wave of cytokine target gene expression can be initiated by IRFs. The 
interplay between STATs and IRFs thus enables the cell to prolong and fine-tune the 
effect of the cytokine signal it has received. 
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2 REVIEW OF THE LITERATURE 
2.1 Cytokines 
In multicellular organisms intercellular communication is essential for the 
maintenance of homeostasis. Direct cellcell contacts, contacts with the extracellular 
matrix, and signals delivered by soluble mediators provide the cell with information 
from the extracellular environment. This information is then integrated at the 
cellular level and interpreted into changes in the transcriptional profile of the cell. 
This ultimately leads to decisions concerning cell fate, e.g. growth, differentiation, 
and apoptosis. 
Cytokines are soluble mediators that usually operate at very low concentrations in 
auto- or paracrine fashion. One exception is the diffusible chemotactic gradient 
created by chemokines, where local concentrations of the chemokine can reach high 
levels. Many different cell types can produce a given cytokine. The cytokine system 
displays two typical features: redundancy and pleiotropy. Two individual cytokines 
can be structurally very distantly related, but may nevertheless have very similar, or 
redundant, effects on their target cells. On the other hand, a particular cytokine may 
have a range of different target cells, where it regulates distinct cell type-specific 
processes, referred to as pleiotropy. Cytokine function in the target cell can be 
modulated by other cytokines or mediators (e.g. prostaglandins) simultaneously 
present. Often stimulation with two cytokines results in synergistic potentiation of 
the cytokine signals, but two opposing cytokines can also antagonize each others 
effects on the target cell. A cytokine can also induce or inhibit the production of 
other cytokines, leading to the generation of cytokine cascades. A key determinant 
in cytokine responses is the expression of a suitable cell surface receptor. Receptor 
expression may be regulated developmentally or induced by cytokines or cellcell 
contact. The cytokinereceptor interaction can be further modulated by expressing 
soluble or non-signaling decoy receptors, or receptor antagonists that are able to 
inhibit cytokine binding and subsequent intracellular signaling initiated by the 
receptor [1, 2]. 
Cytokines function as intermediates in controlling cell growth and differentiation 
and in regulating inflammatory reactions and the activation of antimicrobial defence 
systems. Classification of cytokines into families based on their structure is not very 
informative since cytokines are structurally very heterogenous. More traditionally, 
cytokines have been classified into families broadly based on their functions (Table 
1), or alternatively, by the structure of their receptors (Table 2) [1, 2]. 
 18 
Table 1. Classical cytokine families 
Cytokine family Cytokines Biological activities 
Interleukins (ILs) IL-1IL-31 
numerous overlapping 
and nonredundant 
activities, e.g. regulation 
of cell growth and 
differentiation, 
proinflammatory effects, 
immune cell activation 
Interferons (IFNs) IFN-α, -β, -γ, -λ, -ω, -τ 
antiviral, 
antiproliferative, 
immunomodulation 
Tumor necrosis factors (TNFs) TNF-α, TNF-β proinflammatory, 
apoptosis 
Transforming growth factor 
(TGF)-β family 
TGF-βs, inhibins/activins, bone 
morphogenetic proteins 
morphogenesis, 
development, 
immunomodulation 
Chemokines 
chemokines (C, CC, CXC, and  
CX3C types) 
chemotaxis, immune cell 
activation 
Colony stimulating factors 
(CSFs) 
GM-CSF, G-CSF, M-CSF, IL-3 
growth and 
differentiation of 
hematopoietic cells 
Growth factors EPO, TPO, EGF, FGF, PDGF 
growth and 
differentiation of cells 
Adapted from [1, 2]. 
 
As cytokines are potent activators of diverse cellular processes, it is no surprise that 
their expression is controlled at multiple levels. Transcription of most cytokine 
genes requires the concerted action of several transcription factors, activated by 
diverse ligands, to certify that the incoming signals are properly integrated. The 
stability of cytokine mRNAs is also regulated, as many of them contain signals for 
rapid degradation in the 3 untranslated regions. Some cytokines (e. g. IL-1β and IL-
18) require posttranslational processing to attain functional maturity. In addition, the 
secretion of mature cytokines can be a regulated process. Also, cytokines (e.g. TGF-
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β) can interact with the extracellular matrix to regulate their availability to target 
cells after secretion. 
 
Table 2. Classification of cytokines based on receptor subclass 
Cytokine receptor family Receptor subtype Ligands 
Cytokines sharing βc IL-3, IL-5, GM-CSF 
Cytokines sharing γc 
IL-2, IL-4, IL-7, IL-9, IL-13, IL-
15, IL-21 
Cytokines sharing gp130 or a 
related protein 
IL-6, IL-11, IL-12, IL-23, IL-27, 
LIF, OSM, CNTF, G-CSF 
Type I (hematopoietin) 
Single-chain receptors GH, EPO, PRL, TPO 
Type II (IFN) - IFN-α/β, IFN-γ, IL-10 family 
Type III (TNF) - TNF-α, TNF-β 
Type IV (IL-1) - IL-1 family, IL-18 
Receptor tyrosine kinase - M-CSF, PDGF, EGF 
CXC receptors CXC chemokines 
Chemokine 
CC receptors CC chemokines 
TGF-β - TGF-β family 
Adapted from [1]. 
2.2 Cytokine signal transduction pathways 
2.2.1 Receptor systems utilized by cytokines 
In contrast to structurally divergent cytokines, cytokine receptors can be grouped 
into families based on conserved structural features (Table 2). The type I (also called 
the hematopoietin receptor family) and type II (IFN receptor family) cytokine 
receptor families are structurally closely related. Receptors belonging to these 
families do not contain enzymatic activity, but are instead associated with 
cytoplasmic kinases capable of transmitting the extracellular signal inside the cell. 
Many type I and all type II receptors are composed of multiple subunits. In the case 
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of type I receptors, one of the subunits (or even two in the case of IL-2 and IL-15) 
can be shared between different receptor complexes. Three subgroups, sharing 
signal transducing chains βc, γc, or gp130, can be distinguished. Some receptors 
belonging to the type I receptor family consist of only one type of subunit (single-
chain receptors), but the active receptor is a homodimer or homo-oligomer. Type III 
or TNF-family receptors form homotrimers, to recognize their trimeric ligands. 
Instead of activating cytoplasmic kinases, these receptors signal by homotypic 
proteinprotein interactions. Some growth factors utilize receptors containing 
inherent tyrosine kinase activity. Ligand binding to these receptors leads to receptor 
chain dimerization and activation of the kinase domains through conformational 
changes. Chemokine receptors belong to the seven-transmembrane domain receptor 
family utilizing trimeric G-proteins in intracellular signaling. TGF-β receptors, in 
turn, contain serine/threonine kinase activity [1-4]. 
2.2.2 The JAKSTAT pathway 
Transduction of cytokine signals from the type I and type II cytokine cell surface 
receptors to the nucleus is mediated by the JAKSTAT pathway (reviewed in [5, 6]; 
Fig. 1). This pathway was first identified in the context of IFN signaling (reviewed 
in [7]). JAK tyrosine kinases associate with the cytoplasmic domains of cytokine 
receptor chains. Cytokine binding leads to homo- or heterodimerization, or in some 
cases heterotrimerization, of the receptor chains. According to the present model, 
these events trigger the activation of the JAK kinases [8, 9]. For the EPO receptor it 
has been demonstrated that in addition to receptor dimerization, conformational 
changes in the receptor are required for Jak2 activation [10, 11]. Juxtaposed JAKs 
auto- or transphosphorylate each other and specific tyrosine residues on the receptor 
chains. This creates docking sites for proteins containing the phosphotyrosine-
binding SH2-domain. One group of such proteins is the STAT family. STAT 
proteins dock onto their target cytokine receptors and become phosphorylated on 
specific C-terminal tyrosine residues by JAKs. Some STATs require additional 
serine phosphorylation for full transcriptional competence (reviewed in [12]). 
Phospho-STATs disengage from the receptor to form homo- or heterodimers, and 
are then transported to the nucleus, where they bind to their target DNA sequence, 
the GAS element (consensus sequence TTCN2-4GAA) [13]. 
The classical STAT activation pathway described above is associated with cytokine 
stimulation. STAT activation is usually rapid and transient in nature and is quickly 
down-modulated to keep cytokine responses under control. More recently, Stat1 has 
also been found to participate in the regulation of constitutive gene expression. 
Basal expression levels of certain caspase genes and the gene coding for low 
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molecular mass polypeptide 2 are lower in Stat1-null cells compared to the parental 
cell line. Basal expression is rescued to normal levels by reintroducing Stat1 or a 
mutant form of Stat1 that cannot be tyrosine-phosphorylated and cannot therefore 
form dimers. This suggests that Stat1 can also function in a non-tyrosine-
phosphorylated form in target gene regulation [14, 15].  
The JAKSTAT pathway is negatively regulated by several different mechanisms 
(reviewed in [16, 17]). The cytokine receptor can be endocytosed and lysosomally 
degraded, terminating the initiating signal. Protein tyrosine phosphatases, like CD45 
and SHP-1, are responsible for dephosphorylation of the JAKs and the receptor 
phosphotyrosines. STAT DNA-binding can be down-regulated by tyrosine 
dephosphorylation and degradation [16, 18]. More specific mechanisms inhibiting 
STAT activity include the SOCS and PIAS family proteins (reviewed in [17, 19-
21]). 
The SH2-domain-containing, cytokine-inducible SOCS proteins bind to 
phosphotyrosines in cytokine receptors or JAKs, and inhibit JAK activity and STAT 
activation by blocking the required docking sites [19, 20]. Additionally, SOCS 
proteins function as ubiquitin E3 ligases, thereby mediating proteasomal degradation 
of interacting proteins, like the STATs. Constitutively expressed PIAS proteins 
target activated STATs to prevent their DNA-binding and/or transcriptional 
activation (reviewed in [17, 21]). Recently, PIAS proteins have been found to 
function in an analogous manner as SUMO-1 ligases for STAT proteins (reviewed 
in [22, 23]), but the importance of this feature in regulating cytokine signaling still 
remains to be elucidated. SUMOylation, unlike ubiquitination, does not target 
proteins for proteasomal degradation. SUMOylation may function as a marker 
sequestering activated STAT dimers and other transcription factors into specific 
nuclear compartments, and in this way have an impact on regulation of transcription 
[21, 24, 25]. 
Several cytokines promote the growth of their target cells, and the JAKSTAT 
pathway is also involved in cell growth regulation (reviewed in [26]). Inappropriate 
activation of STATs (especially Stat1, Stat3, and Stat5) occurs in primary human 
tumor cells as well as in transformed cell lines (reviewed in [27-29]), and STATs 
regulate the expression of many genes controlling cell growth. In human acute 
lymphoblastic leukemia, the Jak2 kinase domain is involved in a chromosomal 
translocation that creates a constitutively active Jak2Stat5 pathway, directly 
contributing to the malignant phenotype [30-32]. Also, epigenetic silencing of SOCS 
expression may be responsible for constitutive activation of the JAKSTAT 
pathway [33]. Some cytokines, like IFNs, also have antiproliferative effects, but 
neither cellular transformation nor development of leukemia occurs in the gene 
knock-out mouse models of this pathway (Table 3 and 4). 
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Figure 1. Regulation of the JAKSTAT pathway by cytokine stimulation. Cytokine 
stimulation leads to dimerization of the receptor chains. This juxtaposes the 
receptor-associated JAK kinases leading to their activation and tyrosine 
phosphorylation of the receptor chains and JAKs. Cytoplasmic STATs are 
recruited to specific phosphotyrosines in the receptor and are also tyrosine-
phosphorylated. Phosphorylated STATs disengage from the receptor and form 
dimers via phosphotyrosineSH2-domain interactions. STAT dimers are 
actively transported into the nucleus where they bind to GAS elements in the 
promoters of cytokine-regulated target genes. SOCS family proteins are 
cytokine-inducible, and function in down-modulating STAT responses by 
binding to activated JAKs and receptor phosphotyrosines preventing STAT 
activation. Constitutively expressed PIAS proteins also inhibit STAT DNA-
binding activity by direct proteinprotein interactions. 
 23 
J A K s  
Four different JAK kinases are found in mammals, namely Jak1, Jak2, Jak3, and 
Tyk2 [34-41]. They are ubiquitously expressed, with the exception of Jak3 that is 
only expressed in hematopoietic cells. A given JAK kinase can be activated by a 
variety of cytokine receptors (Table 3). The structure of the JAKs is unusual as they 
contain, in addition to a functional kinase domain, a catalytically inactive 
pseudokinase domain [5]. This domain regulates both the basal and cytokine-
induced activity of JAKs  [42-44]. Also, JAKs lack SH2- and SH3-domains, protein-
protein interaction domains typical for cytoplasmic tyrosine kinases. 
Mice with targeted disruptions of the JAK genes have been generated (Table 3) [45-
52]. Gene deficiencies reveal some characteristic signaling defects, but as targeting 
of Jak1 and Jak2 results in perinatal or embryonic lethality, tissue-specific gene-
targeting studies could yield more information on JAK functions. 
 
Table 3. Activation of JAKs by cytokines and phenotypes of JAK-deficient mice 
Activating cytokines JAK Phenotype of knock-out mice 
IFNs, IL-10, 
IL-6 family cytokines,  
IL-2, IL-4, IL-7, IL-9, IL-13, IL-15, 
G-CSF, IL-3, IL-5, GM-CSF 
Jak1 
Perinatal lethality. 
No responses to IFNs, IL-2, IL-4, IL-7, 
IL-9, IL-10, IL-13, IL-15.  
Reduced responses to IL-6 and LIF. 
IFN-γ, IL-6 family cytokines, 
G-CSF, IL-3, IL-5, GM-CSF, 
PRL, EPO, TPO, GH 
Jak2 
Embryonic lethality.  
Lack of  definitive erythropoiesis.  
No responses to IFN-γ, IL-3, IL-5. 
IL-2, IL-4, IL-7 Jak3 Severe combined immunodeficiency.  
IFN-α/β, IL-6 family cytokines,  IL-10 Tyk2 
Subtle defects in IFN-α/β- and IL-10-
signaling, defective responses to IL-12 
and LPS. 
Adapted from [9, 16, 53]. 
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S T A T s  
The STAT family of transcription factors comprises seven members: Stats 1-4, 
Stat5A and Stat5B, and Stat6 [54-66]. STATs contain a homologous DNA-binding 
domain, an SH2-domain, and a conserved tyrosine that is phosphorylated by JAKs 
in response to receptor activation (reviewed in [5, 67, 68]). The conserved N-
terminal region is required for proteinprotein interactions between STAT dimers 
[69, 70], and promotes cooperativity in DNA-binding. The more divergent C-
terminal end contains the transcriptional activation domain. As is the case with 
JAKs, most STAT proteins are activated by several cytokines, notable exceptions 
being Stat4 and Stat6 that are activated almost exclusively by IL-12 and IL-4, 
respectively [71]. However, generation of STAT-deficient mice has revealed the 
biological specificity of STAT activation (Table 4; reviewed in [68, 72]; [73-84]). 
Additional cytokine target-gene specificity arises from subtle differences in the 
affinities of different STAT dimers to variations in the GAS consensus sequence 
[13]. All STATs except Stat2 homodimerize, which is the most typical dimer form, 
but heterodimerization occurs between Stat1 and Stat2, Stat1 and Stat3, and Stat5A 
and Stat5B [5]. 
 
Table 4. Activation of STATs by cytokines and phenotypes of STAT-deficient mice 
Activating cytokines STAT Phenotype of knock-out mice 
IFNs                         
IL-6 family cytokines 
Stat1 Impaired IFN signaling and antiviral responses. 
IFN-α/β Stat2 Impaired type I IFN-dependent immune responses. 
IL-6 family cytokines, 
G-CSF, IL-2, IL-10 
Stat3 Embryonic lethality. 
IL-12, IFN-α Stat4 Impaired responses to IL-12 (defective Th1 development). 
Stat5A 
Impaired mammary development, partial T cell growth 
defect. IL-2, IL-7, IL-9, IL-15,  
IL-3, IL-5, GM-CSF, 
PRL, GH, EPO Stat5B 
Loss of sexually dimorphic growth in males. Defects in T cell 
growth, NK cell development, and GM-CSF signaling in 
macrophages. 
IL-4, IL-13 Stat6 Impaired responses to IL-4 (defective Th2 development). 
Adapted from [16, 68, 72]. 
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All STAT proteins, with the exception of Stat2, also exist as smaller molecular 
weight variants, referred to as β-isoforms as opposed to full-length α-isoforms. The 
expression patterns of the β-variants differ from ubiquitous to cell type-restricted 
expression, and they originate from alternatively spliced mRNAs, or are 
posttranslationally processed by proteolysis [85, 86]. The truncation is C-terminal 
involving the STAT transcriptional activation domain. Alternatively spliced Stat1β 
supports IFN-α-, but not IFN-γ-induced transcription [87] due to the lack of the 
essential serine phosphorylation site. Alternatively spliced Stat3β, together with c-
jun, activates transcription from a composite element [88], and has distinct roles 
from those of Stat3α [89]. By microarray analyses, Stat4α and Stat4β were found to 
induce partly overlapping but partly unique target genes [90]. Expression of smaller 
forms of Stat5 is detected in hematopoietic progenitor cells [63, 91], and their 
expression is gradually lost during terminal differentiation [92, 93]. The expression 
of Stat6β in murine mast cells limits the effect of IL-4-stimulation in these cells [94, 
95]. Originally, the truncated forms were assigned an exclusively dominant negative 
role in transcriptional regulation [93, 96-99], but increasing evidence supports their 
activity as bona fide transcription factors with their own target gene specificities [89, 
90]. 
In addition to forming STAT dimers, STATs interact with other transcription 
factors. At least members of the IRF family, NF-κB, Sp1, c-jun, and the 
glucocorticoid receptor are known to regulate transcription from adjacent or 
composite DNA-elements (reviewed in [85, 100]). Also, direct interactions between 
STATs and transcriptional coactivators are detected [85, 100]. 
2.2.3 IRFs 
The IRF family has nine members in mammals, of which only IRF6 remains 
functionally uncharacterized (Table 5; reviewed in [101, 102], [103-118]). 
Additional IRF-like proteins are encoded in the genome of human herpes virus-8 
[119]. The members of the IRF family share a homologous DNA-binding domain 
that binds to variations of a direct tandem repeat element termed IRF-E (consensus 
sequence GAAAG/CT/CGAAAG/CT/C) [101, 102]. Viral IRF-homologs interfere with 
the functions of cellular IRFs [120, 121] and inhibit transcriptional activation, 
thereby inhibiting antiviral and growth-suppressive activities of IFNs [122]. IRF 
expression patterns and effects of IRF gene targeting in mice are summarized in 
Table 5. 
The IRF family can be divided into two subfamilies on the basis of participation in 
the IFN response to viruses. IRF3, IRF5, IRF7, and IRF9 are essential for induction 
of IFN-α/β gene expression in response to viral challenge [112, 122-125]. IRF1 and 
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IRF2 also participate in, but are not essential for, the induction of IFN gene 
expression [126]. IRF1 regulates the expression of genes belonging to the IFN 
system, like 2, 5-oligoadenylate synthetase and dsRNA-dependent protein kinase. 
Additionally, IRF1 controls the expression of several other genes involved in innate 
and adaptive immune responses, like gp91phox, IL-12/p40, IL-15, and genes needed 
for MHC class II expression (reviewed in [127]). Expression of IRF4 and IRF8 is 
limited to lymphoid and myeloid cells (Table 5), and they are strongly implicated in 
controlling cellular differentiation and homeostasis of these cell types, as well as 
several aspects of immune responses [128-137]. 
 
Table 5. The expression of IRFs and effect of gene deficiency 
IRF Expression Phenotype of the immune system in knock-out mice 
IRF1 
ubiquitous, strongly cytokine-
inducible 
impaired NK cell development, defective Th1 
responses, defective CD8+ T cell development  
IRF2 ubiquitous 
inherently impaired NK cell development and activity, 
dysregulation of IFN-α/β-responses 
IRF3 ubiquitous defective antiviral response 
IRF4 myeloid and lymphoid cells 
defective CTL and antitumor responses, defects in B 
cell development and antibody production 
IRF5 
lymphoid tissue, peripheral 
blood lymphocytes 
- 
IRF6 
only cDNA sequence data 
available 
- 
IRF7 ubiquitous; IFN-α/β-inducible defective antiviral response 
IRF8 myeloid and lymphoid cells 
defective Th1 responses (lack of IL-12), CML-like 
syndrome 
IRF9 ubiquitous defective antiviral response 
vIRFs human herpes virus 8 - 
Summarized from [101, 102]. 
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In the original studies IRF1 and IRF9 (in the context of ISGF3) were described as 
transcriptional activators, whereas IRF2, IRF4, and IRF8 were denoted as repressors 
[101, 102]. However, the repressor function seems to depend on promoter DNA 
elements and interacting transcription factors. To date, IRF2, IRF4, IRF5, and IRF8 
have been found to either activate or repress gene expression, depending on the 
target gene (reviewed in [101, 102, 138, 139]). IRFs form several inter-family 
homo- or heterodimers. In addition, IRFs have been found to interact with basal 
transcription machinery proteins [140-143] as well as several other transcription 
factor family members [144-149]. 
Several IRFs are posttranslationally modified by phosphorylation on serine residues 
[101]. This modification affects their activity, subcellular localization, and ability to 
interact with other IRFs and other transcription factors. Kinases reported to induce 
serine phosphorylation of various IRFs in biochemical assays include casein kinase 
2, protein kinase A, protein kinase C, IKKε, and TANK-binding kinase-1 [101, 150, 
151]. Several conserved tyrosine residues are found in the IRF DNA-binding 
domain, but so far tyrosine phosphorylation has been found to regulate the DNA-
binding of IRF8 only [152]. 
Initially, IRF1 and IRF2 were described as having antioncogenic and oncogenic 
potentials, respectively, when overexpressed [153, 154]. IRF1 regulates the cell 
cycle [155] and DNA damage-dependent apoptosis [156]. In the human genome, the 
IRF1 gene maps to the chromosomal region 5q31.1 [157]. Deletions encompassing 
this region are frequently found in patients with leukemia or preleukemic 
myelodysplastic syndrome. Expression of IRF4 in human T cells is induced by the 
Tax oncoprotein of HTLV-1 [111]. Also, a chromosomal translocation involving the 
IRF4/multiple myeloma-1 and Ig heavy-chain loci is frequently found in patients 
with multiple myeloma [158]. Mice with disrupted IRF8 gene develop a human 
CML-like syndrome [131]. Altered expression of IRF8 is likely to be involved in the 
pathogenesis of the human disease as well, as CML-patients express only very low 
numbers, if any, of IRF8 transcripts [159]. IFN-α is used as a therapeutic agent in 
the treatment of CML, and an increase in IRF8 expression correlates with a 
favorable cytogenetic response to IFN-treatment [160]. 
2.2.4 NF-κB 
The mammalian NF-κB/Rel family has five members, NF-κB1 (p50), NF-κB2 
(p52), RelA (p65), RelB, and c-Rel. They all contain an N-terminal Rel homology 
domain that mediates NF-κB homo- or heterodimerization, DNA-binding, and 
binding to inhibitory IκB-proteins (reviewed in [161-163]). The Rel homology 
domain also contains the nuclear localization signal. NF-κB dimers interact with 
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inhibitory IκB proteins in the cytoplasm [161-163]. NF-κB1 and NF-κB2 are 
synthesized as precursor proteins of 105 kDa and 100 kDa, respectively. These 
precursor proteins contain internal IκB-like regions and require proteolytic 
processing to generate the active form. IκB interaction prevents nuclear 
translocation of NF-κB dimers by masking the nuclear localization signal. Cellular 
stimulation activates the classical IKKα/β/γ complex that phosphorylates the IκB 
proteins and targets them for proteasomal degradation, thereby enabling active NF-
κB dimers to enter the nucleus. The NF-κB response is regulated by a negative feed-
back loop: NF-κB dimers activate the expression of IκB that is able to terminate the 
NF-κB response by binding to NF-κB dimers and causing their dissociation from the 
DNA (reviewed in [161, 164]). Proteasomal degradation of activated NF-κB dimers 
is also involved in regulating the length of the NF-κB response [165]. 
NF-κB functions as a central regulator of the cellular stress response. It is activated 
by inflammatory cytokines (e.g. TNF-α, IL-1, IL-18), growth factors, bacteria and 
viruses, UV irradiation, certain therapeutic agents, complement, and oxidative stress, 
among others [161, 164]. NF-κB signaling pathway is involved in the control of the 
cell cycle, apoptosis, lymphocyte development and maturation, as well as neuronal 
cell function [161, 166, 167]. Target genes activated by NF-κB include adhesion 
molecules, cell-surface receptors, chemokines, ILs, and growth factors. Specificity 
in NF-κB target gene regulation is achieved through several mechanisms. Not all 
NF-κB dimers are formed with equal efficiency (Table 6), and the RelA(p65)- and 
NF-κB1(p50)-homodimers and p65/p50-heterodimers are the most common ones 
[162, 168]. Individual dimers are differentially activated in response to diverse 
stimuli, and show preference in binding to different subsets of target sites (reviewed 
in [168, 169]). NF-κB1 and NF-κB2 lack a transactivation domain, and homodimers 
of them are transcriptionally repressive. Some NF-κB proteins show cell type-
restricted expression patterns (Table 6), conferring additional specificity of signaling 
[170]. Also, several IκB isoforms exist with distinct affinities towards different NF-
κB dimers [164]. Interestingly, distinct NF-κB dimers regulate the immediate and 
sustained NF-κB-induced transcriptional activation during DC maturation, and a 
temporally regulated exchange of NF-κB dimers takes place at several target 
promoters [171]. 
Recently, an alternative NF-κB pathway involving NF-κB2/p100 processing by 
nuclear factor-inducing kinase (NIK)/IKKα was identified [172]. It is activated with 
slower activation kinetics than the canonical pathway by a group of receptors 
belonging to the TNF receptor family. This pathway is essential for lymphoid organ 
development and adaptive immunity. Especially important is the activation of 
RelB/NF-κB(p52) dimers by the lymphotoxin β -receptor [173]. Splenic architecture 
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and B cell functions are affected in mice with deletions in genes coding for the 
activators and signaling intermediates of this pathway [162, 163].  
 
Table 6. Expression patterns of NF-κB proteins and possible dimer combinations 
NF-κB protein Expression pattern Dimerization partners 
NF-κB1(p50) ubiquitous RelA(p65), RelB, c-Rel, NF-κB1(p50) 
NF-κB2(p52) ubiquitous RelA(p65), RelB, c-Rel, NF-κB2(p52) 
RelA(p65) ubiquitous RelA(p65), c-Rel, NF-κB1(p50), NF-κB2(p52) 
RelB hematopoietic cells NF-κB1(p50), NF-κB2(p52) 
c-Rel hematopoietic cells RelA(p65), c-Rel, NF-κB1(p50), NF-κB2(p52) 
 
2.2.5 The MAPK pathway  
The MAPK family consists of four related subfamilies: the ERKs, the JNKs, p38, 
and ERK5 (reviewed in [174, 175]). The MAPKs themselves are serine/threonine 
kinases that phosphorylate direct targets in the cytoplasm or inside the nucleus. 
Additionally, they phosphorylate and activate various downstream protein kinases 
[175]. MAPKs are activated by MAPK kinases (MAPKKs), a family of dual-
specificity kinases that activate the MAPKs by both threonine and tyrosine 
phosphorylation. MAPKKs are activated by serine/threonine phosphorylation by 
upstream MAPK kinase kinases (MAPKKKs). The signaling pathways activating 
MAPK cascades include Ras/Raf, Ras/PI3K, and Cdc42/Rac pathways, and 
receptor-coupled trimeric G-protein signaling [174, 176]. IFN-α/β can activate the 
p38 MAP kinase [177]. 
MAPK signaling pathways are activated by inflammatory cytokines, growth factors, 
and cell stress, resulting in changes in the expression levels or intercellular 
localization, altered DNA-binding or transactivation capacity of various 
transcription factors [175]. These transcription factors then activate the expression 
of genes involved in inflammation, apoptosis, regulation of growth, and cellular 
differentiation. The ERK and JNK kinases have been linked to the regulation of the 
JAKSTAT pathway as potential kinases responsible for C-terminal STAT serine 
phosphorylation. Apparently, serine phosphorylation of a given STAT can be 
mediated by various MAPK pathway kinases, depending on the signaling pathway 
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involved (reviewed in [12, 177]). Also, signals from the same receptor can enhance 
the serine phosphorylation of different STATs via distinct pathways [12]. 
One target of the MAPK pathway is the Ets transcription factor family. The Ets 
family consists of approximately 30 members in mammals, and includes both 
transcriptional activators and repressors (reviewed in [178, 179]). Ets transcription 
factors control the expression of many receptors for hematopoietic growth factors 
and cytokines, like GM-CSF, M-CSF, G-CSF, and IL-2. Several Ets factors interact 
with STATs and IRFs, among others, in target gene regulation [179, 180]. 
The MAPK pathways also influence the activity of the AP-1 complex, a dimeric 
transcription factor formed by members of the Jun/Fos family of transcription 
factors. MAPKs act both by increasing the expression and stability of AP-1 
components and by directly stimulating AP-1 activity (reviewed in [181, 182]). In 
addition to the JAKSTAT pathway and Ets and AP-1 transcription factors, the 
MAPK pathway regulates the activity of several additional transcription factors 
(reviewed in [175]). 
2.3 Chromatin and transcriptional control 
Eukaryotic DNA in the nucleus is packaged into chromatin by association with 
specific proteins. The chromatin is a highly dynamic structure where densely 
packed, transcriptionally silent areas exist alongside more relaxed, open areas of 
actively transcribed genes. Also other cellular processes like DNA replication and 
mitosis affect the packaging ratio of the chromatin. The basic unit of chromatin is 
the nucleosome, where the DNA is wrapped twice around a unit of eight histone 
molecules. Approximately 150 bp of DNA is associated with the core histones 
(comprising dimers of histones H2A, H2B, H3, and H4). Histone H1 is located 
outside the core particle, presumably interacting with the linker DNA between 
adjacent nucleosomes [176]. There are variants of histones that affect the structure 
and functionality of the nucleosome (reviewed in [183]), like the H2A.Z variant that 
is involved in preventing the spread of heterochromatin into euchromatic 
chromosomal areas [184], and H3.3 that it a marker for transcriptionally active 
regions in Drosophila [185]. The nucleosome fiber is further packed into poorly 
characterized higher-order structures together with other structural proteins. 
To assist the interaction between promoter DNA elements and regulatory 
transcription factors, and to enable transcription to initiate and proceed, the barrier 
formed by the chromatin structure must be circumvented. Two main classes of 
enzymes are used by the cell in this process, the ATP-dependent chromatin 
remodeling complexes (e.g. SWI/SNF complex) and enzymes able to covalently 
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modify histones (e.g. histone acetyl transferases, or HATs) (reviewed in [186, 187]). 
These regulators seem to act in a synergistic manner to alter the chromatin structure, 
but their order of action is still somewhat controversial and may differ depending on 
the cellular process or the target promoter [186, 187]. For example, in the late 
phases of yeast mitosis, chromatin remodeling is a prerequisite for HAT recruitment 
[188, 189], but in transcriptional induction of the human IFN-β gene, HAT activity 
is essential for the recruitment of SWI/SNF-like remodeling enzymes [190]. There is 
evidence that transcription factors and gene promoters show specific requirements in 
recruiting transcriptional coactivators with HAT activity [191]. 
2.3.1 Chromatin remodeling enzymes 
The chromatin remodeling complexes are large aggregates of proteins. They use the 
energy derived from ATP-hydrolysis to cause reorganization of the nucleosomal 
structure in a non-covalent manner (reviewed in [192]). Three main groups of such 
complexes are ISWI, Mi-2, and SWI/SNF families of chromatin remodelers [186, 
192]. Function of ISWI and Mi-2 complexes is mainly associated with 
transcriptional repression, whereas SWI/SNF complexes are activators. Possible 
mechanisms leading to nucleosome remodeling include sliding of histone octamers, 
transfer of histones to another DNA molecule, and induction of conformational 
changes in either histones, DNA, or both [186]. Nucleosomal sliding does not 
increase the amount of exposed DNA, but only changes its localization. Different 
complexes may use different remodeling mechanisms, depending e.g. on the 
nucleosomal density of the target chromatin area [186]. 
Two models have been proposed for the action of the SWI/SNF enzyme complex. In 
both models, a twist in DNA is formed in an ATP-dependent manner. This twist 
then creates a wave of accessible DNA on the histone octamer. In the first model, 
the SWI/SNF complex tracks along the DNA, simultaneously inducing torsional 
stress. The second model proposes that the twist is created by continuously inducing 
helix deformation. In both cases, the action of the SWI/SNF enzymes only disrupts 
the DNAhistone interface, leaving the histones in place and histonehistone 
interactions intact [187]. Both transcriptional activators and general transcription 
machinery may be able to recruit the SWI/SNF complex to specific promoters [193]. 
2.3.2 Histone modifying enzymes 
Histones are highly basic proteins with a globular structure. However, the amino-
terminal tails of histones protrude from the nucleosome, and specific lysine, 
arginine, and serine residues are available for covalent modification. Histones are 
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targets for several different chemical modifications: acetylation, methylation, 
phosphorylation, ubiquitination, ADP-ribosylation, and glycosylation (reviewed in 
[194, 195]). These modifications can modulate the DNA-packing ability of the 
histones by decreasing their net positive charge. Alternatively or additionally, they 
may create docking sites for interacting proteins [194]. Accordingly, many 
transcriptional coactivators, i.e. activator proteins that do not directly bind to DNA 
but bind to DNA-binding proteins instead, contain bromodomains and 
chromodomains, protein domains recognizing acetylated and methylated lysine 
residues, respectively [195]. 
HATs are the enzymes responsible for acetylation of histones, and their action is 
opposed by histone deacetylases (HDACs). Acetylation of histones can destabilize 
higher-order chromatin structures [187], and amino-terminal histone acetylation is 
linked to transcriptional activity of a given gene. This modification is reversible, and 
deacetylation is known to repress transcription. Many transcriptional coactivators 
contain inherent HAT activity. In addition to acetylating histones, these enzymes 
target also non-histone proteins, like sequence-specific transcription factors. 
Histone methylation has several consequences, such as gene activation or repression, 
or heterochromatic gene silencing, depending on whether the target residue is an 
arginine or a lysine [194-196]. Furthermore, a lysine can be mono-, di- or 
trimethylated [195, 197]. Methylation of histones is considered a stable epigenetic 
mark [198], as no histone demethylases have been identified. However, nucleosomal 
histone methylation status can be altered and involves histone exchange [198]. 
Histone phosphorylation may regulate protein interaction events by creating a 
charge patch rich in negatively charged residues [195]. Phosphorylation of the 
linker histone H1 leads to increased dissociation from the chromatin in Tetrahymena 
[199]. Histone acetylation and phosphorylation are also implicated in repairing 
double-stranded breaks in the DNA [195]. 
T h e  h i s t o n e  c o d e  
In the year 2000, B.D. Strahl and C.D. Allis coined the histone code hypothesis 
[200]. This hypothesis maintains that a particular biological outcome is dictated by 
the sum of histone modifications present in the nucleosomes. The association of 
additional proteins with chromatin is controlled by the specific histone modification 
patterns, and this association leads to changes in the functional state of the DNA 
involved. This model necessitates the existence of proteins able to create the histone 
code (histone modifying enzymes), and proteins able to decipher it (bromodomain- 
and chromodomain-containing proteins). Strict histone modification patterns can be 
detected in various chromatin regions, like actively transcribed areas or 
transcriptionally silent regions. Recently, the histone acetylation code for the IFN-β-
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promoter has been resolved [201], supporting the histone code hypothesis. The 
sequential order in which these modifications take place is significant, and some 
modifications are a prerequisite for, or prevent, a subsequent modification. This type 
of regulation can also be extended in trans from one histone tail to another [202, 
203]. All in all, recent evidence supports the concept of the histone code, but at the 
same time underlines the complexity of this regulatory mechanism. 
2.3.3 The enhanceosome concept 
The promoters and enhancers controlling eukaryotic gene expression consist of 
several short DNA elements able to recruit and interact with sequence-specific 
transcription factors. These modules bestow the regulatory regions with the ability to 
integrate various signals and to form protein surfaces able to recruit chromatin 
remodeling complexes and histone modifying enzymes. The paradigm of such 
control is the virus-inducible IFN-β enhancer (reviewed in [187, 204]). This 
enhancer is located between two positioned nucleosomes, and contains the binding 
sites for NF-κB, IRF, and ATF/c-Jun proteins. Transcriptional activation of the IFN-
β gene requires that all these specific factors are present together with the HMG I(Y) 
protein. The role of the HMG I(Y) protein is to produce structural alterations in the 
DNA to enable the formation of a stable proteinDNA complex termed the IFN-β 
enhanceosome. The enhanceosome complex then recruits, in highly regulated 
sequential order, distinct coactivators with HAT activity, the chromatin remodeling 
complex SWI/SNF, and basal transcription machinery proteins, including RNA 
polymerase II, leading to nucleosome remodeling and initiation of transcription 
[190]. The T cell receptor α chain enhanceosome, which is developmentally 
regulated, and the TNF-α enhancer, which hosts a collection of binding sites used 
selectively by different stimuli, are examples of other well-characterized 
enhanceosome structures [204]. 
2.3.4 Transcriptional coactivators in cytokine signaling 
Global transcriptional coactivators containing HAT activity, like proteins belonging 
to CBP/p300, PCAF/GCN5, TAF250, and SRC1 families, are involved in histone 
acetylation and transcriptional coactivation together with a plethora of different 
sequence-specific transcription factors (reviewed in [205]). Signaling proteins 
mediating cytokine signal transduction make no exception: STATs, IRFs, and NF-
κB require various coactivator-HATs as partners in target-gene regulation. 
Stat1 [191, 206, 207], Stat2 [208], and most likely also Stat4 [209, 210] interact with 
the CBP/p300 HATs. Stat3, Stat5 and Stat6 interact with both CBP/p300 and SRC 
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coactivators to obtain full transcriptional activity [211-217]. Stat5 apparently 
requires glycosylation of a specific residue to interact with CBP [218]. IRF1 and 
IRF2 interact with p300 and PCAF [141, 142]. IRF3 and IRF7, the two IRFs that are 
essential for type I IFN gene induction, show an interesting difference in their ability 
to interact with coactivators. IRF3, but not IRF7, binds CBP, p300, and PCAF [143]. 
This feature, together with slight differences in DNA-binding specificity, may form 
the basis for their differential function in regulating IFN-α/β gene expression. In 
IFN-γ-stimulated monocytes, IRF1, IRF8, and PU.1 form a complex able to recruit 
CBP, and this interaction is essential for the transcriptional induction of the gp91phox 
promoter [140]. Also NF-κB proteins RelA(p65) and NF-κB1(p50) interact with 
CBP/p300, PCAF, and SRC coactivators [219-221]. 
Lately it has become increasingly evident that other DNA-binding proteins in 
addition to histones are targeted by coactivator-HATs as well. Transcription factors 
acetylated by different HATs include, among others, p53, MyoD, HMG I(Y), 
GATA-1, E2F1, and c-Myb [205]. IRFs are also targets of the coactivators HAT 
activity. PCAF acetylates IRF7 on a lysine residue located in the DNA-binding 
domain, and this modification inhibits the DNA-binding activity of IRF7 [222]. 
IRF1 and IRF2 are acetylated by p300 and PCAF [141, 142], and in the case of 
IRF2, this modification serves to target IRF2 to growth-regulated promoters [223]. 
RelA(p65) and NF-κB(p50) are also acetylated by CBP/p300 on several residues 
located mainly in the DNA-binding domain [224-226]. Acetylation of RelA(p65) 
regulates the transcriptional and DNA-binding activity, nuclear export, and IκBα-
association of RelA(p65)(reviewed in [227]). 
2.4 The immune system 
The immune response can be divided into innate and adaptive responses. Physical 
barriers like the skin function as part of innate immunity by preventing pathogen 
entry. Phagocytic cells (monocyte/macrophages and neutrophils), NK cells, 
complement, and cytokines are the principal components of innate immunity. 
Characteristically, they exist before infection, their responses are rapidly activated, 
and their activation does not directly result in generation of immunological memory. 
Pathogen recognition in innate immunity relies on receptors encoded in the germ 
line, like the TLRs, NODs, CD14, scavenger receptors, and mannose-binding lectin 
[228-233]. These receptors recognize conserved structures common to pathogens but 
missing in the host itself. The receptors of antigen-specific adaptive immunity, 
antibodies and T cell receptors, display a vast degree of variability. They are 
selected on the basis of their affinity towards their ligand, and are generated by 
somatic gene rearrangements. Activation of adaptive immune responses is 
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characterized by a time lag of several days. The innate response protects the host 
during this period, and is a prerequisite for the successful initiation of the antigen-
specific immune response. 
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Figure 2. Hematopoiesis. The development of different lineages of blood cells 
schematically illustrated. Blood cells differentiate from pluripotent stem cells 
in the bone marrow. Bone marrow stromal cells secrete cytokines that are 
responsible for stimulating the proliferation and maturation of precursor cells. 
Dendritic cells can originate from both myeloid and lymphoid progenitors. 
CFU, colony-forming unit. Adapted from [234]. 
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The shift from innate to adaptive immune responses is elicited by antigen-presenting 
cells (APCs). Macrophages and DCs are professional APCs that internalize 
extracellular antigens by phagocytosis, endocytosis, and pinocytosis, and subject 
them for specific intracellular processing events to create short antigen-derived 
peptides. These peptides are then presented in the context of MHC molecules to T 
cells to initiate adaptive immune responses. These cellcell contacts between APCs 
and T cells and cytokines present in the cellular environment shape the development 
of both innate and adaptive immune responses by guiding the differentiation of 
immune cells and influencing their activation and functional maturation. 
2.4.1 The monocyte lineage 
Monocytes and monocyte-derived macrophages and DCs are a part of the myeloid 
cell lineage, together with erythrocytes, granulocytes, and megakaryocytes (Fig. 2). 
Some DCs originate also from the lymphoid lineage. Monocytes and macrophages 
are important mediators of innate immune responses due to their phagocytic 
potential and ability to produce a range of cytokines with proinflammatory, 
immunomodulatory, proliferative, and differentiation-inducing properties. 
Macrophages are also able to act as APCs, thus activating adaptive immune 
responses. DCs are unique APCs in the respect that they are able to activate also 
naive T cells, and DCs are the major cell type responsible for initiating the adaptive 
phase of the immune response. 
Precursors for monocytes, as for other blood cells, reside in the bone marrow. Their 
differentiation from the pluripotent stem cells is a multi-step process guided by 
interactions with the bone marrow stromal cells and cytokines, mainly CSFs and 
various ILs (reviewed in [235-237]). Monocytes are a mature cell type with the 
ability to phagocytose foreign antigens and produce cytokines upon activation. 
Monocytes leave the bone marrow and enter the circulation. However, monocytes 
achieve full functional maturation only when they leave the blood stream and enter 
tissues, either in normal peripheral tissues or at sites of inflammation, where they are 
actively recruited by chemokines. 
M a c r o p h a g e s  
Macrophages are monocyte-derived tissue-resident cells that are relatively long-
lived [238]. They are involved in normal homeostasis as they phagocytose apoptotic 
cells and participate in wound healing. Liver Küpffer cells, microglia of the central 
nervous system, lung alveolar macrophages, and bone osteoclasts all represent 
tissue-specific macrophage classes with their own specialized functional profiles 
[239]. A wide variety of transcription factors guides the generation of the 
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monocyte/macrophage population. One of the most important factors directly 
affecting monocyte/macrophage differentiation is the Ets-family transcription factor 
PU.1 (reviewed in [240]). Together with other factors, including C/EBPα and 
AML1, it controls the expression of the M-CSF receptor, thus making developing 
monocyte precursors responsive to the lineage-determining cytokine M-CSF [236, 
237]. IRF8 is also important for monocyte development, as IRF8 gene targeted mice 
have a severely reduced and functionally defective monocyte/macrophage 
population, and they display enhanced granulocyte colony formation instead [130, 
131]. 
Macrophages are activated by various inflammatory signals, like microbial products, 
such as LPS, and cytokines, e.g. TNF-α and IFN-γ (reviewed in [241]). Activated 
macrophages migrate to sites of inflammation. These cells are capable of killing and 
degrading intracellular microbes. They produce inflammatory cytokines, oxygen 
radicals, and lipid mediators [241]. Many of these substances can have deleterious 
effects on the surrounding tissue. Macrophage activity can be down-modulated by 
immunoregulatory cytokines such as IL-10 and TGF-β. 
D e n d r i t i c  c e l l s  
Immature DCs in the tissues are in a constant state of vigilance, and they monitor 
their surroundings by macropinocytosis, receptor-mediated endocytosis, and active 
phagocytosis (reviewed in [242]). Following the emergence of microbial threat, 
immature DCs leave the peripheral tissue to migrate to the local lymph nodes with 
the captured antigen. Mobilization and maturation of DCs are complex processes 
involving loss of phagocytic potential and changes in the expression of adhesion 
molecules, costimulatory ligands, chemokines and chemokine receptors on the 
surface of the DC [242]. In the lymph node, DCs select the few CD4+ Th cells able 
to recognize the specific antigen. Th cells are then responsible for propagating the 
activating signal to other cells of the adaptive immunity. The phenotype of the DCs 
initiating the adaptive immune response can widely influence the outcome of the T 
cell response: cytokine secretion by the DC, antigen concentration and number and 
identity of costimulatory molecules on the DC give information on the nature and 
localization of the pathogen to the T cell [243, 244]. In addition to their role in 
bridging innate and adaptive immunity, DCs are also involved in the formation of 
peripheral immunological tolerance [245]. 
The human DC population comprises several specialized subtypes that differ in their 
differentiation lineage, phenotype, function, and localization in the body. Epidermal 
Langerhans cells, interstitial DCs, and plasmacytoid DCs are generally recognized 
as distinct subtypes [246]. However, there is considerable phenotypical and 
functional plasticity among DC subtypes, and the expression of distinct cell-surface 
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markers may reflect the maturation or activation status or tissue origin of DCs rather 
than define clear-cut subpopulations. Gene-targeting studies in mice have pointed 
out a role for several transcription factors, like Ikaros, RelB, PU.1, and IRF8, in 
generating functional DCs [134-137, 247, 248]. 
2.4.2 NK cells 
NK cells are bone marrow-derived cells that belong to the lymphocyte lineage. They 
function in innate immune responses by directly lysing virus-infected and tumor 
cells. Additionally, they produce high quantities of cytokines, e.g. IFN-γ, TNF-α, 
and GM-CSF, which regulate the development of adaptive immunity. The bone 
marrow stromal environment is critical for the generation of NK cells. Flt3L-
signaling and an intact IL-15/IL-15R-system (including IL-15, IL-15Rα, IL-2Rβ, γc, 
Jak3, and Stat5) are also essential [249]. IL-15 is also required for homeostasis of 
peripheral NK cells. Recent findings indicate that IL-21, a T cell-derived cytokine, 
regulates the transition from innate to adaptive phase of the immune response by 
limiting NK cell activity [250]. 
Activation of NK cells (expansion of the NK cell population and augmented 
cytolytic capacity) can be mediated by target recognition and/or cytokine stimulation 
(reviewed in [249]). One class of NK cell receptors are inhibitory receptors that 
recognize self-MHC molecules [251]. This recognition precludes NK cell activation. 
Stimulatory, non-MHC-restricted NK cell receptors exist but their ligands remain 
largely uncharacterized [251]. NK cell activity is stimulated by several cytokines 
produced by infected DCs and macrophages, like IFN-α/β, IL-12, IL-15, and IL-18 
[249]. Upon viral infection peripheral NK cells rapidly proliferate, and a two-phase 
model of NK cell activation has been proposed [252]. According to this model, in 
the early stages of infection, NK cell proliferation is activated nonspecifically by 
cytokines, and at the later stages, by specific interaction of activating NK cell 
receptors with virus-infected target cells [252]. 
2.4.3 T lymphocytes 
T and B lymphocytes are the effector cells of specific immune responses. They 
express antigen-specific cell-surface receptors, the TCR on T cells and surface Ig on 
B cells, that specifically recognize peptides presented by APCs. The recognition of 
the cognate peptide in its proper MHC-context, additional costimulatory signals 
provided by other receptor-ligand interactions and the presence of a proper cytokine 
environment triggers the activation and clonal expansion of T and B cells, and 
execution of their effector functions. The main function of the B cell population is to 
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produce antibodies of various classes. The T cell population is divided into two 
groups, the CD8+ CTLs and the CD4+ Th cells. CTLs lyse infected or transformed 
target cells. The role of Th cells is to provide stimuli that activate B cell antibody 
production or macrophage effector functions and enhance CTL cytotoxicity. 
Immunological memory is one of the hallmarks of adaptive immunity, and both T 
and B cells contribute to protection from reinfection. For T cells, both CD4+ and 
CD8+ memory cells exist [253]. Regulatory T cells form another important T cell 
subset. These cells function to maintain peripheral tolerance, and control 
autoimmunity, allograft rejection, and inflammatory reactions [254]. Regulatory T 
cells function by producing cytokines that suppress immune responses, like IL-10 
and TGF-β, or by direct cell-cell contacts [254, 255]. 
T h 1  a n d  T h 2  c e l l s  
Following activation by DC antigen presentation, naive CD4+ Th cells further 
acquire more specialized effector phenotypes. These phenotypes can be broadly 
classified as promoting cellular, or Th1, and humoral, or Th2, immune responses. 
The Th1 type immune response is characterized by the production of the hallmark 
cytokine IFN-γ by Th cells, and entails coordinated activation of phagocytes, 
production of opsonizing antibodies, and induction of CTLs. In contrast, Th2 type 
cells secrete IL-4. These cells activate eosinophils, mast cells, and basophils, and, in 
addition, stimulate IgE production by B cells (reviewed in [256, 257]). 
The generation of Th1 and Th2 phenotypes is guided by the cytokine milieu at the 
time of activation of naive T cells. These cytokines can also be used for in vitro 
generation of Th1 and Th2 type cells. Infected APCs usually produce IL-12, IFN-
α/β, IL-18, IL-23, and IL-27, and all of these cytokines, either alone or 
synergistically, induce the production of IFN-γ by T cells, thus favoring Th1 
responses [258]. IL-4 is the major cytokine regulating the generation of Th2 cells. 
Furthermore, Th1 and Th2 cytokines antagonize each others effects, e.g. by 
selectively down-regulating cytokine production and receptor gene expression [256, 
257, 259]. 
Several cytokine-regulated transcription factors are involved in determining the Th 
cell phenotype. Stat4 and Stat6, responsible for signaling by IL-12/IFN-α and IL-4, 
are required for Th1 and Th2 responses, respectively. IFN-γ induces the expression 
of the transcription factor T-bet, which in turn promotes the expression of IL-12R 
and IFN-γ, creating a positive feedback loop strengthening Th1 polarization. IL-4 is 
involved in the induction of the transcription factor GATA-3, which is expressed in 
naive CD4+ Th cells at low levels, and is strongly induced in Th2 cells [256, 257, 
259]. 
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Structural changes that persist after cell divisions are also detected in the chromatin 
surrounding IL-4 and IFN-γ loci during Th cell differentiation. T-bet and GATA-3 
have been implicated in participating in the nucleosome remodeling process in Th1 
and Th2 cells, respectively [256]. Also, transcriptional activity during different 
stages of Th1/Th2 polarization correlates with changes in histone acetylation of the 
IL-4 and IFN-γ genes [256, 257]. 
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Figure 3. Cooperation of immune cells in microbial infections. During infection, DCs 
and macrophages recognize microbial structures and respond to them by 
producing a range of cytokines. In combination with cellcell contacts, these 
cytokines activate NK and T cell effector functions. Activated NK and T cells 
also produce several cytokines, including IFN-γ. At the site of inflammation, 
IFN-γ enhances macrophage activation and antigen presentation to T cells. 
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3 AIMS OF THE STUDY 
Cytokines guide the differentiation and functions of immune cells by regulating the 
activation and expression of specific transcription factors. Two transcription factor 
families, STATs and IRFs, are central in mediating cytokine responses. Genetic 
studies in mice have provided a wealth of information on how these transcription 
factors function in, and are essential for, cytokine responses. However, it is 
recognized that the function of the mouse immune system differs from its human 
counterpart in both innate and adaptive responses. Therefore, differences may exist 
also in the detailed mechanisms by which the cytokine signal in the cell is 
transmitted. 
The aim of this study was to analyze cytokine-induced STAT and IRF transcription 
factor activity and gene expression in primary human blood cells involved in innate 
and adaptive immune responses. 
The specific aims of the study were: 
1. To characterize STAT and IRF expression and activation during 
differentiation of monocytes to macrophages or DCs. 
2. To analyze the effect of cytokine stimulation on STAT and IRF expression 
and DNA-binding in mononuclear cells. 
3. To elucidate the factors regulating the expression of IRF4 in mononuclear 
cells. 
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4 MATERIALS AND METHODS 
4.1 Cell culture 
Leukocyte-enriched buffy coats were obtained from voluntary healthy blood donors 
(provided by Finnish Red Cross Blood Transfusion Service, Helsinki, Finland). In 
each experiment, cells from 2-6 blood donors were used to minimize interindividual 
variation. Cells from different donors were cultured separately, and pooled when 
collected. In all cell cultures, RPMI 1640 medium was supplemented with penicillin 
(0.6 mg/ml), streptomycin (60 mg/ml), glutamine (2 mM), and HEPES (20 mM). 
Inactivated fetal calf serum (FCS; Integro, Zaandam, the Netherlands) was added to 
overnight PBMC cultures (5% FCS), and NK, T cell, and DC cultures (10% FCS). 
The purity of isolated cell populations was monitored by flow cytometric analyses 
with cell-type specific antibodies specified in references (I-IV). Doses and suppliers 
of cytokines and other reagents used to stimulate the cells are described in close 
detail in references (I-IV). 
4.1.1 Isolation of PBMC (I- IV) 
Human PBMC were isolated by density gradient centrifugation over a Ficoll-Paque 
gradient (Amersham Biosciences, Uppsala, Sweden). The cells were washed three 
times and cultured overnight in RPMI 1640 medium on six-well plates (Nunclon; 
20x106 cells/well). 
4.1.2 Monocyte isolation and differentiation of macrophages (I, II, IV) 
To isolate monocytes, purified PBMC were adhered onto plastic six-well plates 
(Falcon) for 1 hour at 37°C in RPMI 1640 medium (10-20x106 cells/well). After 
incubation non-adherent cells were removed and the wells were washed three times 
with cold PBS, pH 7.4. The cells were grown in Macrophage-SFM medium (Life 
Technologies) supplemented with antibiotics, and stimulated and harvested the next 
day. To obtain macrophages, monocytes were differentiated in Macrophage-SFM 
medium supplemented with antibiotics and GM-CSF (10 ng/ml) for 3-7 days. Fresh 
medium was replaced every two days. The purity of the macrophage population was 
> 90%. 
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4.1.3 Purification and differentiation of DCs (IV) 
PBMC isolated by Ficoll-Paque gradient centrifugation were additionally 
centrifuged over a Percoll gradient and washed twice with RPMI 1640 medium. The 
cells were further purified by removing T and B lymphocytes using 
immunomagnetic beads (Dynabeads; Dynal, Oslo, Norway). After washing, cells 
were seeded on six-well plates (Falcon) and monocytes were allowed to adhere for 1 
hour at 37°C in RPMI 1640 medium (2.5x106 cells/well). After washing once with 
PBS, cells were grown in RPMI 1640 medium with 10% FCS, GM-CSF (10 ng/ml), 
and IL-4 (20 ng/ml) for 3-7 days. Fresh medium (1 ml) was added every two days. 
At 7 days the purity the DC population was >90%.  
4.1.4 Isolation and activation of T cells and polarization of CD4+ T cells 
(III) 
Monocytes were removed from PBMCs by adherence and nonadherent T cells were 
further purified by nylon wool columns. Purified T cells were activated with 0.5 
mg/ml immobilized anti-CD3 mAb (R&D Systems, Abingdon, UK) and cultured in 
RPMI 1640 medium supplemented with 10% FCS and 100 IU/ml IL-2 for 5-6 days. 
Cells were further expanded for 5-6 days with RPMI 1640 containing IL-2, at which 
point >99% of the cells were CD3 positive. In all experiments, the cells were 
removed from IL-2-containing medium before cytokine stimulations.  
For lymphocyte polarization studies, lymphocytes were isolated from cord blood of 
healthy neonates and were further purified with magnetic beads (Dynal). Cells 
(2x106/ml) were cultured in Yssel's medium (Irvine Scientific, Germany) containing 
1% AB-serum (Gemini Bioproducts, CA). Cells were primed with 
phytohemagglutinin (100 ng/ml; Murex Diagnostics, France), and grown in the 
presence of feeder cells (irradiated, CD32-B7-transfected mouse L-fibroblasts). For 
Th1 cultures, cells were supplemented with IL-12 (2.5 ng/ml), and for Th2 cultures 
with anti-IL-12 Ab (10 mg/ml) and IL-4 (10 ng/ml). After 48 h priming, IL-2 (40 
IU/ml) was added into the cultures to enhance proliferation. The cells were cultured 
for 7 days. 
4.1.5 Primary NK cells and NK-92 cell line (III) 
NK cells were purified from nonadherent PBMCs by nylon wool columns and two-
step density gradient centrifugation by Percoll (Amersham Biosciences), followed 
by depletion of monocytes and T and B lymphocytes with magnetic beads (Dynal). 
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NK cells were cultured in RPMI 1640 medium with 10% FCS. The purity of the NK 
cell population was > 90%. 
Human NK-92 cell line [260] was maintained in continuous culture in MEM Alpha 
Medium (Life Technologies) supplemented with 12% horse serum (Life 
Technologies), 12% FCS (Integro), 0.2 mM i-inositol, 20 mM folic acid, 40 mM 2-
mercaptoethanol, 2 mM L-glutamine, 0.6 mg/ml penicillin, 60 mg/ml streptomycin, 
and 100 IU/ml human rIL-2. 
4.2 mRNA expression analyses 
To study the influence of cellular differentiation or cytokine treatment on the cell 
population, changes in cellular gene expression were studied. Total cellular RNA 
was isolated either by the guanidium isothiocyanate/cesium chloride method [261, 
262] or by using an RNA purification kit (Qiagen, Germany). 
4.2.1 Northern blotting (I-IV) 
Equal amounts of RNA were size-fractionated on 1% formaldehydeagarose gels, 
transferred to a nylon membrane (Hybond, Amersham Biosciences), and hybridized 
with cDNA probes. Ethidium bromide staining of ribosomal RNA bands or 
hybridization with probes of housekeeping genes GAPDH or β-actin was used to 
ensure equal RNA loading. The probes were labeled with α-32P-dATP (3000 
Ci/mmol, Amersham Biosciences) by random priming. The membranes were 
hybridized at 42° (in buffer containing 50% formamide, 5x Denhardt's solution, 5x 
SSPE and 0.5% SDS; or in Ultrahyb; Ambion, Austin, TX), washed twice at room 
temperature and once at 60oC in 1x SSC/0.1% SDS for 0.5 h each time, and exposed 
to Kodak AR X-Omat films at -70oC using intensifying screens. 
4.2.2 Quantitative RT-PCR (III) 
cDNAs were prepared using Superscript II kit (Gibco). Primers and probes were 
designed using Primer Express software (Applied Biosystems, CA). Gene 
expression levels were measured using TaqMan RT-PCR (ABI Prism 7700, Applied 
Biosystems). Housekeeping gene EF1a was used for normalization of the results. 
The statistical significances of the differences between Th1 and Th2 samples were 
determined with the t-test. 
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4.2.3 cDNA microarray analysis (IV) 
The human Immunochip cDNA microarrays were manufactured in the Finnish DNA 
Microarray Centre at Turku Centre for Biotechnology (www.btk.utu.fi). The 
ImmunoChip contains ~2000 genes implicated in immune cell activation and 
differentiation, including cytokines, chemokines and their receptors, transcription 
factors, and genes involved in signalling, apoptosis, and cell cycle regulation. All 
samples were labeled with FluoroLink Cy3-dUTP and Cy5-dUTP (Amersham 
Biosciences) using 16 µg total RNA for direct labeling during cDNA synthesis and 
hybridized using loop-design [263]. Separate images for Cy3 and Cy5 dyes were 
acquired, and gene transcript levels were determined from the fluorescence 
intensities of the scanned data image. 
4.3 Protein expression analyses 
In this study, two methods were employed to study the effect of differentiation and 
cytokine stimulation on protein expression and function. Direct Western blots were 
used to detect changes in protein expression levels. A more sensitive approach, 
immunoprecipitation, was used for studying proteinprotein interactions and protein 
phosphorylation. 
4.3.1 Western blotting (I-IV) 
Aliquots of whole cell or nuclear extracts (10-30 mg protein) were separated on 
SDS-PAGE using the Laemmli buffer system. Proteins were transferred onto 
Immobilon-P membranes (Millipore, Bedford, MA). Binding of primary and 
secondary Abs was performed in PBS (pH 7.4) containing 5% non-fat milk for 1 h at 
room temperature. Antibodies used in immunoblotting are specified in the Materials 
and methods of original publications (I-IV). The protein bands were visualised on 
Hyper-Max film using the enhanced chemiluminescence system (Amersham 
Biosciences). 
4.3.2 Immunoprecipitation (II) 
Whole cell lysates were cleared by centrifugation and immunoprecipitated with 
specific antibodies using ProteinAsepharose beads. After washing, the bound 
proteins were released in SDS sample buffer and equal aliquots were subjected to 
SDS-PAGE and Western blotting. 
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4.4 DNA protein interaction studies 
DNAprotein interactions on the chromatin level were studied by ChIP. In this 
method cells are fixed and their chromatin is sheared. Specific antibodies are used to 
precipitate pieces of chromatin containing particular proteins, and the occurrence of 
definite DNA fragments among the precipitates is detected by e.g. PCR. To study 
the specific interactions between transcription factor complexes and DNA elements 
found on gene promoters, two methods were employed: EMSA and DNA affinity 
binding assay. In these methods, both strands of the chosen DNA elements (Table 7) 
were synthesized with appropriate spacers (DNA Technology, Aarhus, Denmark). 
The oligonucleotides were annealed in 0.5M NaCl. For EMSA, nuclear extracts 
were prepared [264], and whole cell extracts were used for DNA affinity binding 
assays [265]. 
4.4.1 Chromatin immunoprecipitation (IV) 
The level of histone acetylation in a promoter region correlates with the availability 
of the chromatin to the transcriptional machinery. Higher acetylation levels are 
associated with higher transcription rates. Detection of histone-H3 acetylation of the 
IRF4 promoter was done by using a commercial ChIP kit (Upstate Biotechnology, 
Lake Placid, NY) according to the manufacturers instructions. Macrophages and 
DCs were treated as specified in the kits protocol. The primers from the IRF4 gene 
promoter region used in PCR were 5-ACAGCGCCTGGCCTATTTTG-3 
(forward) and 5-TGCATCTATTAGGCTGGTGA-3 (reverse). Input controls, 
representing the starting material prior to immunoprecipitation, were included in the 
PCR, alongside with the immunoprecipitated anti-acetyl-H3 samples and no-
antibody control samples. PCR samples were analyzed by agarose gel 
electrophoresis on 1.5% gels. 
4.4.2 EMSA (I-III) 
The oligonucleotide was radioactively labeled by Klenow fill-in or by T4 
polynucleotide kinase end-labeling. Nuclear protein/DNA binding reactions (RT, 
0.5h) contained 2-10 µg nuclear extract protein. The samples were analyzed by 
electrophoresis on 6% non-denaturing low-ionic strength polyacrylamide gels in 
0.25x TBE. The gels were dried and DNA/protein complexes were visualized by 
autoradiography. For identification of proteins contained in the complexes, samples 
were incubated with transcription factor-specific antibodies for 1 h on ice (supershift 
analysis). 
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4.4.3 DNA affinity binding assay (II-IV) 
In this method biotinylated oligonucleotides were used and incubated with 
streptavidinagarose beads (Neutravidin; Pierce, Rockford, IL) at +4°C for 2 h, in a 
ratio to yield maximum saturation of the beads with the oligonucleotide. Protein 
samples were incubated with these beads for 2 h at +4°C. After washing, the bound 
proteins were released in SDS sample buffer and equal aliquots were subjected to 
SDS-PAGE and Western blotting. 
 
Table 7. Sequences of DNA elements used in EMSA and DNA affinity binding assays 
DNA 
element 
Sequence (5→3) Used in 
ISRE15 AGCTTGATCGGGAAAGGGAAACCGAAACTGAAGCCA I 
IRF1 GAS AGCTTCAGCCTGATTTCCCCGAAATGACGGA I, II, III 
Pim-1 GAS ACACACATCCCTTCCCAGAAATCAGGATTC II 
CIS GAS1 CCCCGTTTTCCTGGAAAGTTTTGGAAATCTGT II 
CIS GAS2 CCGCGGTTCTAGGAAGACGCTGCTTCCGGGAAGGGCTGG II 
IRF4 GAS TTCCTATTTTCTTTTTAGTGAGTGCGATGTTCTCTAAACACCGC III 
λB TCTTGGTTTCACTTCCTTTTATTTCTG III 
IRF4combi GGCCATTTCCTATTTTCTTTTTAGTGAGTGCGATGTTCTCTAAACACCGC IV 
CD68 CCTCTCTTGGAAAGGAGGAAATGAAAGTC IV 
NF-κBRE1 AAAGTATGTAAAATCCCTGGTCCA IV 
NF-κBRE2 TCGGCTTGCAAAGTCCCTCTCCCC IV 
Stat6/κB CCTCGCCCTTCGCGGGAAACGGCCCCAGTGACAGTCCCCGAAGC IV 
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5 RESULTS AND DISCUSSION 
In this study, leukocytes isolated from human peripheral blood were used as the cell 
model to study the effect of cytokines on the expression and functions of STAT and 
IRF transcription factors. Primary leukocytes are natural targets for cytokine action. 
In addition, several STATs and IRFs show cell type-specific expression patterns, 
with prominent expression particularly in hematopoietic cells. Thus, leukocytes 
provided the framework in which to study the biological functions of STATs and 
IRFs in their proper cellular context. 
5.1 STAT and IRF expression in mononuclear cells 
5.1.1 Up-regulation of STAT and IRF gene expression in response to 
IFNs (I) 
In the beginning of this work, studies on STATs had concentrated on elucidating the 
molecular mechanisms and the identity of actual amino acid residues involved in 
JAKSTAT signaling. Only few reports had addressed the question of cytokine 
regulation of STAT and IRF gene expression [266, 267]. Expression and activation 
of STAT factors was shown to depend on the state of development and cellular 
differentiation [268]. This study was undertaken to clarify how IFN-stimulation 
affected the expression of IFN signaling molecules in human PBMCs and 
macrophages (I). 
In most cells Stat1 and Stat2 are ubiquitously and constitutively expressed. In (I) we 
studied the expression of Stat1 and Stat2 using human PBMCs and monocyte-
derived macrophages. IFN-α and IFN-γ were both able to strongly up-regulate Stat1 
and Stat2 mRNA and protein expression (I, Figs. 1-6). In addition to STATs, also 
members of the IRF family take part in mediating IFN signal transduction. IRF9 
(formerly p48) is a component of ISGF3, the IFN-α-specific signal transduction 
complex together with Stat1 and Stat2. IRF1 and IRF2 were at the time considered 
to be essential mediators of IFN responses that directly regulate type I IFN gene 
expression. IRF1 and IRF2 were considered to be an activator and a repressor of 
ISGF3/ISRE-mediated transcription, respectively. Expression of IRF1, and to a 
lesser extent IRF2 and IRF9, was up-regulated by IFNs in PBMCs and macrophages 
(I, Figs. 1-7). Increased expression of STATs and IRFs could not be blocked by 
inhibition of protein synthesis with cycloheximide (I, Fig. 8), suggesting that the 
effect of IFNs on STAT and IRF gene expression was direct. 
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Regulation of STAT gene expression in normal, non-transformed cells still has not 
been thoroughly investigated. Expression of IFN signal transducing components has 
been studied in various cancer cell lines, where retinoids and IFNs have been found 
to significantly increase expression of Stat1, Stat2, IRF1, or IRF9 [269-273]. The 
IRF9 promoter is reportedly regulated by c-myc, and by CCAAT/enhancer binding 
protein β in response to IFN-γ-treatment [274-276]. However, in these studies, 
induction of IRF9 expression was demonstrated to require de novo protein synthesis, 
contrary to the results in (I) where inhibition of protein synthesis did not block IRF9 
mRNA expression. In most cell lines, basal IRF9 expression is very low or non-
existing, contrary to the constitutive expression that is seen in primary mononuclear 
cells (I, Figs. 1, 3, 5, and 8). Expression of IRF9 protein itself may be required for 
direct IFN-induction of IRF9 gene expression. 
The biologic effects of IRF1 are a result of inducible mRNA and protein expression 
[127], and the protein has a short half-life [277]. The IRF1 promoter contains a 
GAS-element [278, 279], and, accordingly, IRF1 gene expression was prominent in 
IFN-stimulated cells (I, Fig. 7), a finding also reported by several other studies [104, 
105, 267]. In macrophages, IRF1 mRNA levels remained high for at least 24 h in 
response to IFN-γ-stimulation in contrast to IFN-α-stimulation where IRF1 mRNA 
levels peaked at 4 hours and declined thereafter. This may be indicative of 
prolonged Stat1 DNA-binding activity in response to IFN-γ-induction compared to 
IFN-α-induction. This phenomenon has been previously described in other cell 
systems as well [272, 280]. In this setting, prolonged expression of the IRF1 protein 
in response to IFN-γ could enhance IFN-induced gene expression by cooperating 
with the IFN-α-induced ISGF3 complex. Alternatively, IRF1 could function 
independently in regulating ISRE-mediated transcriptional activation after the 
ISGF3 complex has dissociated due to inactivation of its components by tyrosine 
dephosphorylation.  
5.1.2 Stat5 expression during macrophage differentiation (II) 
A central cell model in this study is the monocyte/macrophage differentiation model. 
GM-CSF is required for the generation of common monocyte-granulocyte 
precursors in the bone marrow, and M-CSF guides the growth of cells committed to 
the monocytic lineage. Both cytokines are used for in vitro generation of 
macrophages. In this study, GM-CSF, which activates the Jak2Stat5 pathway, was 
used. Therefore, characterization of this signaling pathway during 
monocyte/macrophage differentiation was the intent of study (II). 
The expression of Stat5A and Stat5B mRNAs was not significantly altered during 
differentiation of monocytes to macrophages (II, Fig. 8A). On the protein level, 
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however, two isoforms of both Stat5A (94 kDa and ~77kDa) and Stat5B (92 kDa 
and ~80 kDa) were detected in monocytes (II, Fig. 8B and 9A). In differentiated 
macrophages, only the 94- and 92-kDa forms were expressed (II, Fig. 8B and 9A). 
The expression of smaller forms of Stat5 proteins has been reported in several cell 
types, mainly in cells representing hematopoietic precursor populations [63, 91]. A 
nuclear protease has been identified that proteolytically processed Stat5A and 
Stat5B in the C-terminus [93]. Also, alternatively spliced mRNAs that could account 
for the expression of smaller protein forms have been reported for Stat5 [96, 281, 
282]. These splice variants may be expressed in a cell type-specific manner, because 
in this study only single species of both Stat5A and Stat5B mRNAs were detected 
during monocyte-to-macrophage differentiation in Northern blot analyses. This 
suggests that if alternatively spliced mRNAs are expressed in these cells, their 
expression levels are very low. It may be that two different mechanisms, alternative 
splicing or proteolytic processing, may be used in parallel to generate smaller Stat5 
forms in different cell types or in response to different stimuli. 
Stat5A and Stat5B proteins were found to form both homo- and heterodimers in 
response to GM-CSF-stimulation (II, Fig. 9B). Heterodimer formation has been 
reported previously for Stat5A and Stat5B ([283]; reviewed in [284]). It may be that 
all types of dimers have their own target genes, as they have been shown to display 
subtle preferences in binding to different GAS element sequences [285, 286]. 
5.1.3 Expression of IRFs in NK and T cells (III) 
Cell type-restricted expression pattern is characteristic to two IRF family 
transcription factors, IRF4 and IRF8. They are both expressed in the 
monocyte/macrophage lineage and in lymphocytes. Also, ubiquitously expressed 
IRFs, like IRF1, regulate the expression of many genes in a cell type-specific 
manner. IRF1, IRF4, and IRF8 have a role in initiating adaptive immune responses.  
Both IRF1 and IRF8 are essential for the production of IL-12 [131-133, 287, 288], a 
macrophage-derived cytokine that promotes the generation of Th1 immune 
responses. IRF1 is also needed for proper responsiveness of CD4+ T cells to IL-12 
[288]. In addition to controlling CD4+ T cell functions, IRF1 regulates the 
differentiation of CD8+ T cells by affecting the expression of MHC class I 
molecules [289]. NK cell development also requires IRF1 because it controls the 
expression of the essential NK cell growth factor IL-15 by bone marrow stromal 
cells [290]. 
In humans, both IFN-α and IL-12 are able to promote IFN-γ expression by T cells 
and the generation of Th1 immune responses. These two cytokines are, together with 
IL-2 and IL-15, important activators of NK cells, and are able to induce the 
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production of IFN-γ by NK cells. In (III) the effect of IFN-α- and IL-12-stimulation 
on the expression of IRFs in NK and T cells was studied. IFN-α and IL-12 were able 
to stimulate IRF1, IRF4, and IRF8 mRNA and protein expression in NK-92 cells 
and primary NK cells (III, Fig. 1). In T cells, both IFN-α and IL-12 strongly up-
regulated the mRNA expression of IRF1 and IRF4, but only IFN-α was able to 
induce significant expression of IRF8 mRNA (III, Fig. 2). 
IRF1 is a well-known target gene for IL-12 in NK and T cells [291, 292], as shown 
also by our results. In (III) we showed that IFN-α and IL-12 caused enhanced 
mRNA expression and nuclear protein expression of IRF8 in NK cells. In mouse 
macrophages, it has been reported that IFN-α does not up-regulate IRF8 mRNA 
expression [293]. This is contradictory to our results in NK and T cells, and suggests 
that IRF8 expression in response to IFN-α is under cell type-specific regulation. In 
NK and T cells IRF4 mRNA expression and nuclear accumulation was enhanced by 
both IFN-α and IL-12 (III, Figs. 1 and 2). In B cells, expression of IRF4 is 
constitutive. Antigen receptor cross-linking [110] and PMA-stimulation or HTLV 
Tax-protein expression [111] induce IRF4 expression in mouse and human T cells, 
respectively. Our report (III) was the first to characterize the IRF4 gene as a 
cytokine-responsive gene in NK and T cells. Previously it has been shown that IRF4 
mRNA levels were up-regulated in T cells of chronic myeloid leukemia patients and 
correlated with a favorable response to IFN-α therapy [294]. IFN-α and IL-12 are 
important cytokines in innate immune responses, as they activate IFN-γ production 
by NK cells. That these cytokines also induce IRF4 expression and DNA-binding in 
NK cells could indicate the involvement of IRF4 in regulating innate immune 
responses in addition to its role in adaptive T and B cell responses. To provide 
insight into this matter, NK cell functions should be evaluated in IRF4 knock-out 
mice.    
IRF1 is important for the generation of Th1 type immune responses, and IRF4 is 
essential for T cell cytotoxic and antitumor responses, as well acquisition of Th1 and 
Th2 phenotypes [128, 129, 287, 288]. The expression of IRF1, IRF4, and IRF8 
mRNAs was followed during in vitro polarization of cord blood T cells. Th1 
polarizing conditions strongly favored the expression of IRF1 and IRF8 mRNAs 
compared to Th2 conditions (III, Fig. 3). These results support the role of IRF1 in 
Th1 cells. It is known that IRF8-deficiency leads to defective Th1 differentiation, 
but this results from the failure of APCs to produce IL-12. Our results suggest the 
possibility that IRF8 may play a role in Th1-differentiation on the T cell side as 
well. This question could be answered by studying IRF8 knock-out mice with 
targeted deletion only in T cells. The expression of IRF4 mRNA was more 
prominent in Th2 polarizing conditions (III, Fig. 3). Preferential expression of IRF4 
detected in Th2 cells is supportive of the established role for IRF4 in controlling Th2 
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development [129, 148] and GATA-3 expression [129], but in our cell system, IRF4 
mRNA was expressed also in Th1 polarized cells, albeit on a lower level than in Th2 
cells. Interestingly, in IRF4-deficient mice, the differentiation of both Th1 and Th2 
cells was compromised [129]. In contrast to IRF8-deficient mice, this effect was 
intrinsic to T cells, as proper Th differentiation was not observed when naive T cells 
lacking IRF4 were transferred to wild-type animals.   
5.1.4 STAT and IRF expression during differentiation of monocytes into 
macrophages and DCs (IV) 
Several reports have characterized, by large-scale microarray analyses, the 
differences in gene expression profiles between monocytes, macrophages, and DCs, 
either in the basal state or various infection models [295-301]. We were interested in 
the early changes in gene expression when monocytes are induced to differentiate 
into macrophages or DCs. Monocytes can be differentiated in vitro into 
macrophages by GM-CSF, or into DCs by GM-CSF together with IL-4. We 
analyzed monocytes stimulated with these cytokines by cDNA microarray analysis. 
As a part of this microarray project, IRF4 was found to be one of the most strongly 
up-regulated genes in response to GM-CSF- and IL-4-stimulation, and especially in 
response to the combination of these cytokines. Other IRFs did not show marked 
changes in their expression levels after stimulation (IV, Table 2). The strong 
induction of IRF4 mRNA was confirmed by Northern blotting (IV, Fig. 1). Cytokine 
induction of IRF4 expression has been reported in B cells, where IL-4 was found to 
up-regulate IRF4 mRNA expression [146]. In myeloid cells, (IV) is the first study 
reporting myeloid-specific cytokine-inducibility of IRF4 expression. 
The expression of IRF1, IRF4, and IRF8 was more closely followed during 
macrophage differentiation. IRF1 expression was down-regulated during 
differentiation, and was not inducible by either GM-CSF or IL-4 (IV, Fig. 2). GM-
CSF induced IRF4 mRNA expression only in monocytes, but IL-4 was able to up-
regulate IRF4 expression also in 3-day macrophages (IV, Fig. 2). IRF8 mRNA 
expression was up-regulated by IL-4 but not by GM-CSF-treatment (IV, Fig. 2). 
Interestingly, a previous report showed that monocytes being differentiated into 
macrophages with GM-CSF became DCs when given IL-4 during the first 3-5 days 
of differentiation [302]. Our results also suggest that monocytes differentiating into 
macrophages retain the ability to respond to IL-4, and that IL-4-induced IRF4 
mRNA expression could be a marker of a transcription factor phenotype typical for 
DCs. 
The basal expression of IRF1, IRF4, and IRF8 mRNAs was studied in monocytes, 
macrophages, and DCs (IV). In the basal state, monocytes were the only cell type 
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expressing IRF1. IRF8 was constitutively expressed in all the cell types (IV, Fig. 
3A). IRF8 is required for IL-12 expression by macrophages, for 
monocyte/macrophage and DC differentiation, and for control of myeloid cell 
proliferation [130-137]. Therefore, it is no surprise that IRF8 mRNA is basally 
expressed in all these cell populations. In contrast, constitutive IRF4 mRNA and 
protein expression was almost exclusively found in DCs (IV, Figs. 3A and 5C). The 
expression of IRF4 has previously been detected in mouse macrophages and human 
plasmacytoid DCs [138, 303, 304]. The discrepancies in the observed expression 
patterns between previous studies and (IV) probably reflect differences between 
species and cell models studied. 
Expression of STAT genes was not significantly regulated in response to GM-CSF-
or IL-4-stimulation, when measured by the cDNA microarray analysis. However, as 
the analysis covered only the immediate early events in monocyte differentiation 
into macrophages or DCs, the basal expression of STAT mRNAs in monocytes, 
macrophages, and DCs was studied. Stat1, Stat5A, and Stat5B mRNAs were 
constitutively expressed during differentiation (IV, Fig. 5A, see also II, Fig. 8). Stat6 
expression was more prominent in monocytes and DCs. Clearly detectable Stat4 
mRNA expression, however, was seen only in DCs (IV, Fig. 5A). The expression of 
Stat4 by activated monocytes, macrophages, or mature DCs in Th1 inflammatory 
conditions has been detected in other studies [305, 306], and our report showed 
expression also in immature DCs. In T cells the production of IFN-γ is absolutely 
dependent on Stat4-activation by IL-12 [77, 78]. APCs readily produce IFN-γ in 
inflammatory conditions [307-309], and a similar requirement on Stat4 expression 
and activity may operate in IFN-γ-production by these cells as well. [307-309] 
5.2 Cytokine-induced STAT and IRF DNA-binding activity 
5.2.1 IFN-γ pretreatment enhances the formation of IFN-α-induced 
DNA-binding complexes (I) 
The expression of both reported splice variants for Stat1 (resulting in protein 
products p91 and p84) was up-regulated with comparable intensity by IFNs (I, Figs. 
1, 3, and 5). The p84 variant lacks the serine residue involved in serine-
phosphorylation in the transactivation domain, and is unable to support IFN-γ-
induced gene activation [87]. However, in the context of the ISGF3-complex, p84 
and p91 are functionally equivalent, due to the strong transactivation domain 
provided by Stat2 [310]. Stat1 dimers (termed GAF) were efficiently formed in 
response to both IFN-α- and IFN-γ-stimulation (I, Fig. 9 and 10). In our study (I), 
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the EMSA was not able to separate different combinations of p91/Stat1α and 
p84/Stat1β in Stat1 complexes. Thus, the activation potential of the detected Stat1 
dimers cannot be assessed by this in vitro assay, and it is not possible to determine 
their functionality, distinct from the activity of ISGF3, in IFN-α responses. This 
would require the generation of Stat1α and Stat1β transgenic mice. 
Stat1 dimers mediate signaling in response to both IFN-α and IFN-γ, and Stat1
Stat2 dimer together with IRF9 form the ISGF3 complex participating in IFN-α 
signaling. Accordingly, Stat1-deficient mice are extremely susceptible to several 
viruses due to defective IFN-α- and IFN-γ-signaling, and Stat2- and IRF9-deficient 
mice have defects in IFN-α/β-signaling [73, 74]. In (I) we found that IFNs enhanced 
the expression of IFN signaling components Stat1, Stat2, and IRF9. We further 
showed that when macrophages were primed overnight with IFN-γ followed by 
stimulation with IFN-α, enhanced formation of IFN-α-specific DNA-binding 
complexes, ISGF3 and GAF, was detected (I, Figs. 9 and 10). This may lead to 
enhanced expression of IFN-α target genes in the beginning of the innate immune 
response, when IFN-γ form NK cells and auto- or paracrine IFN-α from 
macrophages are induced by the invading microbe. 
When other IFN combinations were used for priming and stimulation of cells, the 
formation of signaling complexes was significantly diminished (by IFN-γ/IFN-γ and 
by IFN-α/IFN-γ) or totally abolished (by IFN-α/IFN-α). Ligand-induced down-
modulation of receptor cell-surface expression has been reported for both IFN-α and 
IFN-γ [311, 312]. At the time of study (I), negative regulation of STAT signal 
transduction pathways was thought to depend mainly on tyrosine phosphatases 
dephosphorylating the activated cytokine receptors, JAKs, and STATs. The same 
year, however, several groups reported characterization of a novel family of genes, 
now termed SOCS, whose expression is induced by activated STATs. 
To date, SOCS protein family consists of eight members, CIS and SOCS 1-7. The 
expression of SOCS mRNA and proteins is rapidly induced by cytokine- or growth 
factor-stimulation of cells, and also by LPS and chemokines [20]. They contain 
SH2-domains, and are suggested to attenuate cytokine signaling by directly binding 
to phosphorylated tyrosines on cytokine receptor chains and JAKs, thereby 
preventing JAK activity or docking of STATs onto the receptor [17, 20]. 
Additionally, SOCS proteins function as ubiquitin E3 ligases, and target interacting 
proteins for proteasomal degradation. However, many of these studies are based on 
overexpression studies [19], and SOCS expression during normal cytokine 
stimulation has not been comprehensively characterized. In (I) we used various 
combinations of IFN-α and IFN-γ for priming and stimulation of macrophages, and 
studied the effect of these combinations on IFN signaling. In this experimental 
setting, the induction of SOCS gene expression by IFN-priming is likely to play a 
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role in down-modulating the subsequent signaling response to IFN-stimulation 
(combinations IFN-γ/IFN-γ, IFN-α/IFN-γ, and IFN-α/IFN-α). Indeed, the mRNA 
expression of SOCS3 and CIS is induced in macrophages following stimulation by 
IFN-α or IFN-γ, providing at least a partial explanation for the difference in 
signaling efficiency in response to various IFN combinations detected in human 
primary macrophages (Fig. 4). 
0I     1      2     4     8    24    0II   0III
CIS
SOCS3
IFN-α-stimulation IFN-γ-stimulation
time (h)0I     1      2     4     8    24   0II   0III
28S
18S  
Figure 4. SOCS3 and CIS mRNA expression is induced by IFN-α and IFN-γ in 
human macrophages. Macrophages were stimulated with IFN-α or IFN-γ for 
times indicated in the figure or left untreated, and total cellular RNA was 
isolated. 10 µg samples of total RNA were run on gels and analyzed by 
Northern blotting with CIS and SOCS3 probes. 0I, 0II, and 0III represent 
untreated samples collected at 1, 4, and 24 hours. Ethidium bromide staining 
of ribosomal RNAs is shown as a control of equal loading. 
5.2.2 GM-CSF-induced JAKSTAT signaling in differentiating 
macrophages (II) 
Both GM-CSF and M-CSF can be used to generate macrophages in vitro. These two 
growth factors use different receptor systems. GM-CSF uses a type I cytokine 
receptor, with a ligand-specific α-chain and the common βc-signaling chain. M-CSF 
utilizes a receptor with intrinsic tyrosine kinase activity. When studying GM-CSF-
induced Jak2Stat5 activation (II), we discovered that GM-CSF-induced Stat5 
DNA-binding activity was considerably reduced in macrophages compared to 
monocytes (II, Figs. 1 and 5). This was also reflected on the level of mRNA 
expression of two known Stat5 target genes in macrophages (II, Fig. 3). Continuous 
administration of GM-CSF might desensitize the cells and decrease GM-CSF-
induced Stat5-activation in macrophages. To investigate this phenomenon, M-CSF 
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instead of GM-CSF was used for macrophage differentiation, and cells were then 
stimulated with GM-CSF. Identical results were obtained from M-CSF-
differentiated cells: GM-CSF-induced Stat5 DNA-binding and target gene mRNA 
expression were both decreased in macrophages (II, Fig. 4). In addition, mRNA or 
protein expression of GM-CSF receptor components or Jak2 was not significantly 
affected by macrophage differentiation (II, Fig. 7). Jak2 activity, measured by GM-
CSF-induced tyrosine phosphorylation, was actually higher in macrophages that in 
monocytes (II, Fig. 7). The results in (II) strongly suggested that the decreased 
responsiveness of macrophages to GM-CSF is regulated on the level of Stat5, and is 
not caused by down-regulation of the GM-CSF receptor system in these cells. 
Another interesting feature of GM-CSF-induced Stat5 DNA-binding was the finding 
that the DNA-binding complex in monocytes had faster mobility in EMSA gels than 
the respective macrophage complex (II, Figs. 1, 4-6). Supershift EMSA studies with 
Stat5-specific antibodies confirmed that the DNA-binding complexes consisted of 
only Stat5 (II, Fig. 5D). By DNA affinity binding assays we were able to show that 
the 77/80 kDa Stat5 isoforms also participated in the formation of the DNA-binding 
complex (II, Fig. 9C). The expression of smaller Stat5 isoforms has been linked to 
repression of target gene expression in hematopoietic precursor cells expressing 
exclusively the truncated forms with no full-length Stat5 protein expression [63, 91]. 
The results in (II) do not fully support the concept of target gene repression by 
smaller Stat5 isoforms, as the participation of the 77/80-kDa forms in the DNA-
binding complexes did not inhibit CIS and pim-1 expression in monocytes. This may 
be due to the co-expression of the full-length forms, but recent evidence also 
suggests an independent role for the β-forms of STATs in gene regulation [89, 90] 
as opposed to a sole function as dominant negative variants of the α-forms. 
In (II) we used the mRNA expression of two known Stat5-responsive genes, pim-1 
and CIS [313-315], as markers for GM-CSF activity in stimulated cells. Pim-1 is a 
serine/threonine kinase involved in controlling myeloid cell proliferation [313, 316], 
and may be associated with proliferative responses in monocytes. Our results show 
that its expression was strongly reduced in macrophages compared to monocytes (II, 
Fig. 3 and 4B). In addition to the Jak2Stat5 pathway, GM-CSF activates the ERK 
MAPK-pathway and phosphatidylinositol-3-kinase pathway [317]. One main 
function of these signaling pathways is to transmit survival signals in hematopoietic 
cells. By reducing activation of Stat5 in response to GM-CSF stimulation cells may 
control the expression of some proliferation-associated genes, like pim-1, when cells 
are terminally differentiated. At the same time, signaling components upstream of 
Stat5 are left intact, allowing for the transmission of GM-CSF survival signals into 
the cell.  
 57 
CIS belongs to the SOCS family of inhibitors, and it blocks the binding of Stat5 to 
the cytokine receptor and hence the activation of Stat5 [315, 318]. However, in 
monocytes the expression of CIS mRNA was strongly up-regulated already at 1 h 
after GM-CSF-stimulation, and remained on the same high level for at least 24 h, 
displaying no clear signs of inhibition of Stat5 DNA-binding activity (II, Fig 3). CIS 
is a ubiquitinated protein [319], and may target activated receptor chains to 
proteasomal degradation. In differentiating monocyte/macrophages this down-
regulation is apparently transient, as both cell types readily express GM-CSF 
receptor α- and β-chains (II, Fig. 7). The reduced activation of Stat5 caused by CIS 
expression might be compensated by a slower off-rate of Stat5β-containing dimers 
from DNA, and might lead to prolonged Stat5 target gene expression in monocytes. 
The smaller β-isoforms of Stat3 and Stat5 have been reported to display enhanced 
DNA-binding activity [98, 320], thus giving support to this hypothesis. 
Interestingly, in EMSA gels a complex with very low mobility was detected in 
monocytes stimulated with GM-CSF for 0.5h (II, Figs. 1, 4A, 5, 6). This complex 
most likely corresponds to formation of Stat5 tetramers. STAT tetramers reportedly 
form through N-terminal proteinprotein interactions [69, 70] on promoters 
containing several GAS elements. Tetramerization of Stat5 has been reported to 
occur on the CIS promoter used in this study [286, 315] and on the IL-2 promoter 
[321]. Tetramerization is especially important on tandem GAS sites possessing low 
STAT binding affinity [13]. 
5.2.3 IFN-α and IL-12 induce IRF4 and IRF8 DNA-binding in NK and 
T cells (III) 
IRF proteins form complexes with other IRFs as well as other transcription factors. 
IRF1 is generally regarded as a transcriptional activator, but IRF4 and IRF8 have 
dual roles as activators and repressors of gene expression [127, 139, 322]. Their 
function depends on the interacting partners and the target DNA element. Both IRF4 
and IRF8 interact with PU.1, an Ets-family transcription factor expressed in several 
hematopoietic cell lineages. In the context of Ets/IRF sites, IRF4 and IRF8 function 
as transcriptional activators. Known PU.1/IRF targets in lymphocytes include 
enhancers of Ig κ and λ chains and IL-1β, and the promoter of CD20 [323]. 
IFN-α and IL-12 up-regulated IRF4 and IRF8 expression in NK and T cells (III). 
This was also reflected by enhanced nuclear expression of IRF4 and IRF8 proteins.  
Next, the DNA-binding of these transcription factors was studied. In NK cells, IFN-
α and IL-12 enhanced DNA-binding of IRF4 and IRF8 (III, Fig. 4A). In T cells 
similar results were obtained, but the response to IL-12 was weaker compared to that 
of IFN-α. Stimulation of the cells via TCR crosslinking was the strongest inducer of 
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IRF4 and IRF8 DNA-binding (III, Fig. 4B). Interestingly, even though IL-12 did not 
enhance IRF8 mRNA expression in T cells, IRF8 DNA-binding was weakly 
increased in T cells at 6 h after IL-12-stimulation, suggesting that IL-12 has an 
enhancing effect on IRF8 target gene regulation. 
IRF4 and IRF8 are most likely able to bind DNA without specific activation by 
receptors, although tyrosine phosphorylation does regulate some aspects of IRF8 
DNA-binding [152]. Therefore, coordinately up-regulated expression is one means 
to enhance the expression of IRF4/IRF8 target genes [129]. To date, IRF4/IRF8-
specific target genes involved in Th responses have not been identified, but 
comparative microarray gene expression analyses between wild-type and IRF4- or 
IRF8-deficient mice should clarify the role of these transcription factors in different 
aspects of immune responses. 
5.3 Control of IRF4 gene expression 
IRF4 has, until recently, remained one of the least studied members of the IRF 
family. Initial studies reporting IRF4 expression described it as a lymphocyte-
specific IRF. It is constitutively expressed in B cells, and in T cells its expression is 
activated by antigen receptor cross-linking and expression of the oncogenic HTLV 
Tax-protein. The analyses of IRF4-deficient mice revealed that IRF4 is required for 
the maturation of B cells and generation of plasma cells [128]. T cell proliferation 
was reduced, and T cell cytotoxic activity was absent in these mice [128]. 
Furthermore, Th1 and Th2 responses were dysregulated [129]. Later, the expression 
of IRF4 was also detected in the cells of the myeloid lineage, namely monocytes and 
macrophages [138, 303], coinciding with the expression pattern of IRF8. Only a few 
myeloid IRF4 target genes are presently known [322-324]. Perhaps due to 
incomplete expression data available at the time, the question of IRF4 functions in 
DCs was not address by the original knock-out study. Very recently, IRF8 was 
reported to take part in TLR9/NF-κB signaling in DCs [325]. Regarding the close 
relationship and similar expression patterns of IRF4 and IRF8, involvement of IRF4 
in TLR signaling should be examined, as well as the possible DC defects in IRF4 
deficient mice. 
IRF4 promoter analyses in human and mouse describe binding sites for Sp1, AP-1, 
NF-κB, and PU.1 [110, 326, 327]. A later report identified an additional NF-κB-
binding site and a CD28 responsive element in T cells [328]. DNA elements 
conferring cytokine-inducibility of the IRF4 promoter were not reported by these 
studies. In (III) we showed that IRF4 expression in NK and T cells was rapidly up-
regulated by IFN-α and IL-12, suggesting that cytokine-inducible promoter elements 
exist in the IRF4 promoter. Also our own microarray analyses pointed out IRF4 as a 
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gene specifically up-regulated by cytokines relevant to generation of macrophages 
and DCs (IV, Table 2, Figs 1-3A). This prompted us to analyze the constitutive and 
cytokine-inducible expression of the cell type-restricted IRFs in our cell model in 
more detail (III, IV). 
5.3.1 The IRF4 promoter contains a GAS-like DNA element able to 
bind Stat4 in response to cytokine stimulation in NK and T cells 
(III) 
In (III), while studying cytokine-induced expression of IRF4, we identified a GAS-
like DNA element in the IRF4 promoter (III, Fig. 5). The IRF4 GAS showed 
specificity in its STAT-binding pattern. Stat4, but not Stat1 or Stat3, bound to this 
element in response to IFN-α and IL-12 stimulation, even though Stat1 was 
efficiently activated by IFN-α (III, Fig. 5). Binding of Stat4 to this site was strictly 
cytokine-inducible. Of the other IRF genes, at least the promoters of IRF1, IRF7, 
and IRF8 are known to contain a GAS element [267, 329, 330], and these genes are 
also IFN-inducible. Additionally, IRF9 mRNA expression is up-regulated by both 
IFN-α and IFN-γ (I), although the mechanism is likely to be different, as no GAS 
elements have been identified in the IRF9 promoter. Taking into consideration the 
fact that several IRFs function as dimers in the regulation of their target genes, 
coordinated expression of these proteins is probably of importance. This is 
emphasized by the findings reporting that the same cytokines or STAT proteins 
control the expression of many IRFs.  
5.3.2 Detection of histone H3 acetylation levels in the IRF4 promoter in 
macrophages and DCs (IV) 
IRF4 mRNA was constitutively expressed in DCs but no expression could be 
detected in macrophages, (IV, Fig. 3A), suggesting that IRF4 gene expression might 
be regulated at the level of differential promoter accessibility in macrophages and 
DCs. When histones on a promoter region are acetylated, transcription rate from this 
promoter is higher than from promoters associated with non-acetylated histones. We 
performed ChIP experiments using anti-acetyl-histone H3 antibodies to detect 
differences in IRF4 promoter acetylation between macrophages and DCs. The 
results showed that, from both macrophages and DCs, IRF4 promoter-specific 
primers produced a PCR product of the expected size after immunoprecipitation 
with anti-acetyl-histone H3 antibodies (IV, Fig. 3B). These results suggested that 
differences in IRF4 promoter histone acetylation do not explain the difference in 
IRF4 mRNA expression between macrophages and DCs. How, or if, cytokine 
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stimulation affects IRF4 mRNA expression in macrophages remains to be 
elucidated, but our results showed that at least IL-4-stimulation did not induce IRF4 
mRNA expression in these cells (IV, Fig.2).  
5.3.3 IRF4 promoter analysis 
The MatInspector program [331] was used to localize putative transcription factor 
binding sites in the IRF4 promoter region (IV, Fig. 4) of both human and mouse 
origin. The analysis was done in parallel because we wanted to assess evolutionary 
conservation of putative transcription factor binding sites predicted by the program. 
Mouse and human promoters have been partially characterized previously [110, 
326-328]. Sequence analysis yielded several transcription factor binding sites that 
had not been previously reported. Among those relevant to cytokine stimulation, we 
chose three putative NF-κB binding sites, one of which is located adjacent to a 
conserved Stat6-binding site. In addition, we analyzed the functionality of an 
extended IRF4 GAS element. The IRF4 GAS element was extended 8 nucleotides 
upstream (named IRF4combi) because of the predicted presence of a PU.1/IRF4 
binding site adjacent to the GAS element. Of note, the MatInspector program did not 
recognize the functional IRF4 GAS element as a putative STAT binding site.  
S T A T  b i n d i n g  t o  t h e  S t a t 6 / κ B  a n d  I R F 4 c o m b i  
e l e m e n t s  
The GAS element, originally characterized as an IFN-γ-activated sequence that 
binds Stat1 dimers, is found in the promoters of cytokine-inducible genes, and is 
able to bind various STAT dimers. The GAS consensus sequence is TTCN2-4GAA. 
However, some GAS elements show preferential binding of distinct STAT dimers 
while nearly completely excluding the binding of others. Stat6 dimers bind with 
high affinity to GAS sites where the half-sites are separated by four nucleotides (N4-
sites), but are also able to bind to the more common N3-sites [13]. Our computer 
analysis (IV, Fig. 4) and study (III) suggested the presence of two putative GAS 
sites, and the binding pattern of different STAT dimers to these sites was studied in 
DCs (IV). 
The cytokines used in in vitro differentiation of macrophages and DCs, GM-CSF 
and IL-4, activate Stat5 and Stat6, respectively. Stat5 and Stat6 DNA-binding was 
detected only in 7-day DCs (IV, Fig. 5B). The Stat6/κB element bound Stat6 very 
strongly, suggesting that Stat6 is, as predicted, the major factor binding to this site 
(IV, Fig. 5B). Stat6 and NF-κB are known to interact on similar DNA elements 
[332-334]. Stat6 is activated by IL-4 in a wide variety of human cell types, including 
DCs, B cells, and Th2 cells, where IRF4 mRNA was strongly expressed during early 
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phases of IL-4-driven differentiation (III, Fig. 3) [146]. Interestingly, Stat6 binding 
to the Stat6/κB site was strong in 7-day DCs, two days after the last input of GM-
CSF/IL-4. Similar prolonged Stat6 DNA-binding activity has been reported in 
murine B cells [335] during continuous IL-4-stimulation. This experimental setting 
is analogous to the use of IL-4 in the culture medium during differentiation of DCs 
in our cell system and suggests that in DCs, IL-4 elicits a sustained Stat6 DNA-
binding response, even though STAT DNA-binding activity is usually of short 
duration and actively terminated by phosphatases and regulatory proteins. 
Maintaining continuous Stat6 DNA-binding activity could provide a mechanism by 
which Stat6 regulates constitutive target gene expression. In B cells, IL-4-
stimulation up-regulates IRF4 mRNA expression [146], but this report did not 
describe promoter elements that could bind IL-4-activated Stat6. The IRF4 promoter 
Stat6/κB element described in (IV) may support both constitutive and inducible IL-4 
responsiveness in different cell types. 
Basal Stat4 mRNA expression was considerably stronger in DCs than in 
macrophages (IV, Fig. 5A). Accordingly, basal Stat4 DNA-binding to both GAS 
elements was detected only in DCs (IV, Fig. 5B). However, phosphorylation of 
Stat4 could not be directly detected in DCs (data not shown). Nonphosphorylated 
Stat1 and Stat3 are constitutively found in the nucleus of unstimulated primary 
human cells and cell lines [336, 337]. Interestingly, constitutive transcription of 
LMP2 gene is supported by nonphosphorylated Stat1 together with IRF1 [15], and 
constitutive expression of certain caspases depends on the presence of Stat1, not 
requiring its activation or dimerization [14]. Stat4 could reside in the nucleus in 
nonphosphorylated form as well, and participate in basal IRF4 gene regulation in an 
analogous manner. Nonphosphorylated STAT proteins may emerge as common 
mediators regulating constitutive gene expression. 
N F - κ B  b i n d i n g  t o  I R F 4  p r o m o t e r  N F - κ B  e l e m e n t s  i n  
D C s  
Several NF-κB sites have been characterized in the human and mouse IRF4 
promoters [110, 327, 328], and our computer analysis (IV, Fig. 4A) of the human 
IRF4 promoter region revealed the presence of additional putative NF-κB binding 
sites (IV, Fig. 4). NF-κB(p50) and NF-κB(p65) mRNA expression was lower in 
macrophages than in DCs, and the same difference applied to constitutive NF-κB 
DNA-binding (IV, Fig. 6). Similar results have been obtained by others [338, 339].  
Basal binding of NF-κB(p50) protein to Stat6/κB element was detected in all cell 
types (IV, Fig. 6B). NF-κB(p50) homodimers are associated with transcriptional 
repression [340, 341]. More differentiated cells expressed a higher molecular weight 
form of NF-κB(p50) protein compared to monocytes (IV, Fig. 6B). This shift in 
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molecular weight could be due to post-translational modifications of NF-κB(p50). 
Phosphorylation and acetylation of NF-κB subunits have been reported to occur 
[227, 342, 343]. Phosphorylation of NF-κB subunits controls the DNA-binding and 
gene regulatory activity of NF-κB homo- and heterodimers. Basal binding of NF-
κB(p65), RelB, and c-Rel was only detected in differentiated macrophages and DCs. 
Inducible binding of NF-κB proteins to the IRF4 promoter NF-κB elements in TNF-
α-stimulated DCs was also studied in (IV). Using three different oligonucleotides 
containing putative NF-κB binding sites (IV, Fig. 4A) we could show that NF-
κB(p50), RelB, and c-Rel constitutively bound to all of these three elements, with 
some enhanced binding after TNF-α-treatment (IV, Fig. 7A). Strong NF-κB(p65) 
binding was seen in TNF-α-treated DCs (IV, Fig. 7A). DCs display high constitutive 
expression of IRF4 mRNAs (IV, Fig. 3A), and TNF-α stimulation only weakly 
increased the expression of IRF4 mRNA (IV, Fig. 7B). In lymphoid cells, 
constitutively active RelB mediates basal transcription [344, 345]. RelB is also 
essential for the generation of myeloid DCs in the mouse [346]. Constitutive 
expression and DNA-binding activity of RelB may be one of the factors regulating 
basal IRF4 expression in DCs in a cell type-specific manner. 
I R F 4  m a y  a u t o r e g u l a t e  i t s  o w n  g e n e  e x p r e s s i o n  v i a  
t h e  E t s / I R F  e l e m e n t  i n  t h e  I R F 4  p r o m o t e r  
The PU.1/IRF4 element predicted by the MatInspector analysis was found to be 
functional in DNA affinity binding studies (IV, Figs. 5 and 7). IRF4 bound to this 
element only in 7-day DCs (IV, Fig. 5C), although IRF4 protein expression was high 
also in 3-day DCs (IV, Fig. 5C). Basal DNA-binding of IRF4 to the IRF4combi and 
CD68 gene Ets/IRF DNA elements was detected in DCs (IV, Fig. 7C), and the 
binding was enhanced by TNF-α-treatment. IRF8 gene expression is also reported to 
be autoregulated by its own gene product [293]. The fact that both IRF4 and IRF8 
proteins bind to their own promoter regions suggests that autoregulation of gene 
expression is one means of maintaining cell type-restricted expression of these IRFs. 
PU.1, an Ets-family transcription factor, is known to form a gene regulatory 
complex with IRF4 [323]. PU.1 mRNA expression remained unchanged during 
differentiation of macrophages and DCs (IV, Fig. 3A). PU.1 bound to the DNA 
element in 7-day macrophages and DCs, and stronger binding was seen in DCs (IV, 
Fig. 5C). PU.1 is able to bind DNA on its own, but IRF4 binding to Ets/IRF sites 
requires PU.1 [109]. In DNA affinity binding studies, a smaller form of PU.1 was 
consistently detected in monocytes and 3-day cells (IV, Fig. 5C). PU.1 protein 
contains a PEST domain rich in proline, glutamic acid, serine, and threonine 
residues. PEST sequences are thought to be involved in regulating protein stability, 
and proteins carrying this sequence are targeted for rapid proteolytic degradation 
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(reviewed in [347]). However, in the case of PU.1, it is suggested that this region is 
involved in proteinprotein interactions and does not function as a degradation 
signal [348]. In the case of interaction between PU.1 and IRF4, a specific serine 
residue in the PEST region of PU.1 needs to be phosphorylated [349]. In our cell 
system the smaller form of PU.1 was able to bind to DNA, but was apparently 
unable to interact with IRF4 despite IRF4 expression in 3-day DCs. It has previously 
been observed that mere DNA-binding domain interactions between PU.1 and IRF4 
are not strong enough to support formation of the PU.1/IRF4 DNA-binding complex 
[348, 350, 351]. These results suggested that the smaller PU.1 detected in our cell 
system lacks the region necessary to support the PU.1IRF4 interaction. ChIP 
analyses on PU.1 and IRF4 binding on the IRF4 promoter should clarify the roles of 
these factors in successive stages of macrophage and DC differentiation. 
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6 CONCLUDING REMARKS 
The immune system is a network of cells, receptors, and soluble mediators. Immune 
cells are continuously renewing and responding to pathogenic challenges during the 
hosts lifetime. Their gene expression profiles undergo dramatic changes throughout 
the development, differentiation, and cell cycle. Transcription factors are the 
proteins responsible for coordinating these complex processes, from cellular 
differentiation and cell type-specific phenotypes to active proliferation during 
immune responses. It has been estimated that 5% of the genes in the human genome 
encode transcription factors, which underscores the importance of transcriptional 
control in all cellular processes. 
The focus of this work was to characterize STAT and IRF transcription factor gene 
expression and activation in human immune cells. STATs and IRFs regulate 
cytokine-induced signaling in immune cells, and they themselves are cytokine target 
genes. In this study, STATs and IRFs were studied in two different experimental 
settings: normal cellular differentiation and stimulation of cells with inflammatory 
cytokines IFN-α, IFN-γ, and IL-12. 
When monocytes differentiate into macrophages, Stat5 activation and target gene 
expression in response to growth factor stimulation is significantly reduced. 
Different Stat5 isofoms were expressed in monocytes and macrophages. The 
interactions of STAT β-isoforms with other transcription factors and transcriptional 
coactivators in all probability differ from the full-length forms, providing an 
additional level of specificity to gene regulation by STATs. DCs and macrophages 
differ in their expression of IRF4 and Stat4. These transcription factors are likely to 
contribute to the generation of the DC phenotype. Also, determining the role of 
IRF4 in TLR signaling could provide important insights into the differential role of 
DCs and macrophages during innate immune responses. 
Stimulation of macrophages and NK and T cells with inflammatory cytokines 
resulted in up-regulation of Stat1, Stat2, IRF1, IRF4, IRF8, and IRF9 gene 
expression. Cytokine induction of IRF gene expression could strengthen and prolong 
the effect of cytokines in immune cells, and also induce the expression of an 
expanded set of target genes. Cytokine cascades are important in immune responses. 
The expression of many cytokine target genes is turned on only when several 
signaling pathways, like STATs, IRFs, and NF-κB, are activated simultaneously. 
This is exemplified also by the IRF4 promoter, which harbors binding sites for all 
these factors. The immune system is a network of signals, and cytokine signaling is 
mediated by a network of transcription factors. 
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The ability to mount an effective immune response, which includes generation of 
immune cells of the required types, appropriate cytokine milieu, and proper 
temporal regulation, is essential for the survival of the organism. Activation of 
different transcriptional systems by microbes and cytokines and subsequent down-
regulation of these responses are central factors in maintaining host homeostasis. 
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